{"gene":"THRA","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":1986,"finding":"The c-erb-A protein was identified as a high-affinity receptor for thyroid hormone (T3/T4). The protein is nuclear-localized and binds to DNA, while the viral oncogene product v-erb-A is defective in hormone binding but retains nuclear localization.","method":"Hormone binding assays, nuclear localization studies, comparison of c-erbA and v-erbA proteins","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — foundational ligand-binding demonstration, replicated independently in two simultaneous papers (PMIDs 2879242 and 2879243)","pmids":["2879242","2879243"],"is_preprint":false},{"year":1987,"finding":"A novel thyroid hormone receptor (erbA-T/TRα) encoded by a human testis cDNA clone was shown to bind T3 with high affinity (Kd ~0.38 nM), establishing that multiple human thyroid hormone receptor isoforms exist with potentially different tissue specificities.","method":"cDNA cloning, in vitro binding assay (T3 binding with Scatchard analysis)","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — direct binding assay with quantitative Kd measurement","pmids":["3672126"],"is_preprint":false},{"year":1988,"finding":"The c-erbA alpha-encoded thyroid hormone receptor (TRα) is phosphorylated on serine residues at two distinct sites in its amino-terminal domain. Activation of either protein kinase C (PKC) or cAMP-dependent protein kinase (PKA) enhances phosphorylation at one shared site (Ser28/29), and PKA phosphorylates this site directly in vitro, identifying PKA as a writer of TRα phosphorylation.","method":"In vivo phosphorylation labeling, tryptic phosphopeptide mapping, in vitro kinase assay with purified PKA","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay with peptide mapping confirming same site as in vivo phosphorylation","pmids":["2903825"],"is_preprint":false},{"year":1988,"finding":"Alternative splicing of the rat c-erbA alpha (Thra) primary transcript generates r-erbA alpha-2, a protein that retains the DNA-binding domain but lacks T3-binding capacity, and which inhibits T3-dependent transcriptional activation by functional T3 receptors (r-erbA alpha-1 and r-erbA beta).","method":"cDNA cloning, in vitro T3 binding assay, transient transfection reporter assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — reconstituted T3 binding failure confirmed in vitro; functional inhibition shown in cell-based reporter assay; replicated across species","pmids":["2537467","2903438","2554288"],"is_preprint":false},{"year":1988,"finding":"The hormone-binding domain of chicken c-erbA (TRα) resides in the carboxy-terminal half of the protein. Multiple mutations present in the carboxy-terminal half of v-erbA cooperate to abolish hormone binding, and a point mutation between the DNA- and ligand-binding domains that abolishes v-erbA biological activity does not affect hormone binding, indicating this region controls transcriptional activity independently of hormone binding.","method":"Chimeric c-erbA/v-erbA protein analysis, in vitro T3 binding assay, site-directed mutagenesis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with chimeric proteins and mutagenesis pinpointing functional domains","pmids":["3359993"],"is_preprint":false},{"year":1988,"finding":"Both c-erbA-alpha (chicken) and c-erbA-beta (human placenta) can function as hormone-dependent modulators of thyroid-hormone-responsive genes (rat GH and PRL). In receptor-deficient cells both act as classical T3 receptors, while in receptor-containing cells they modulate transcription in a hormone-independent manner, demonstrating that events other than ligand binding can activate TRα.","method":"Transient transfection reporter assays in multiple cell lines (receptor-deficient and receptor-containing)","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — clean cell-based functional assay with defined receptor-null vs. receptor-containing contexts; single lab","pmids":["2903439"],"is_preprint":false},{"year":1989,"finding":"The v-erbA oncogene protein acts as a constitutive transcriptional repressor and dominant negative antagonist of the thyroid hormone receptor (TRα/c-erbA): when coexpressed with TRα, v-erbA blocks thyroid hormone-induced gene activation. Unliganded TRα itself suppresses responsive promoter activity, but hormone converts it to an activator.","method":"Transient co-transfection reporter assays; dominant negative functional analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — clean co-transfection epistasis with defined receptor; replicated across multiple labs","pmids":["2733791"],"is_preprint":false},{"year":1989,"finding":"The c-erbA alpha (THRA) gene locus on chromosome 17 encodes both TRα1 and TRα2 (via alternative splicing) and overlaps with the Rev-ErbA alpha gene, which is encoded on the opposite DNA strand. A 269-bp segment is exonic in both Rev-ErbA alpha and r-erbA alpha-2 mRNAs, generating complementary RNAs from the same genomic locus.","method":"Genomic DNA isolation and sequencing, cDNA cloning, Northern blotting, exon mapping","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — direct genomic sequencing and structural characterization; independently corroborated by multiple labs","pmids":["2542765","2539258"],"is_preprint":false},{"year":1989,"finding":"c-ErbA alpha (TRα) represses AP-1-mediated transcriptional activation of the interstitial collagenase gene promoter by decreasing AP-1 transcription factor activity in a ligand-activated manner. v-ErbA fails to repress AP-1 and instead acts as a dominant negative by overcoming this repression, maintaining a fully active AP-1 complex.","method":"Transient transfection reporter assays, AP-1 activity assays, dominant negative analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — clean cell-based mechanistic dissection of TRα/AP-1 interaction with defined loss-of-function (v-erbA)","pmids":["1682056"],"is_preprint":false},{"year":1989,"finding":"c-erbA alpha (TRα) phosphorylated on serine 12 by casein kinase II (CK2) in vitro at a site matching the consensus CK2 substrate motif with flanking acidic residues. Site-directed mutagenesis (Ser12→Ala) abolished CK2 phosphorylation in vitro, identifying CK2 as the kinase for this N-terminal site. The CK2-phosphorylated serine 12 is conserved across all T3-binding c-erbA alpha family members but absent in v-erbA.","method":"In vitro kinase assay with purified CK2, two-dimensional phosphopeptide mapping, site-directed mutagenesis","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with purified kinase plus mutagenesis confirming site identity","pmids":["2552374"],"is_preprint":false},{"year":1990,"finding":"v-erbA oncoprotein requires phosphorylation at Ser-16/17 (in its v-erbA-encoded domain, corresponding to the PKA/PKC phosphorylation site of c-erbA) for its oncogenic function. Ser→Ala substitution abolished phosphorylation and eliminated the ability to block erythroid differentiation and repress erythrocyte-specific genes (band 3, carbonic anhydrase II), while Ser→Thr preserved basal but not PKA/PKC-enhanced phosphorylation and yielded partial activity. H7 kinase inhibitor recapitulated the differentiation-induction phenotype.","method":"Site-directed mutagenesis, in vivo phosphorylation assay, biological differentiation assay in transformed erythroblasts, protein kinase inhibitor treatment","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with multiple substitutions, orthogonal pharmacological validation, and defined phenotypic readout","pmids":["1979040"],"is_preprint":false},{"year":1990,"finding":"Overexpressed c-erbA (TRα) modulates erythroid differentiation and erythrocyte-specific gene expression in a T3-dependent fashion in erythroid cells. The v-erbA oncoprotein has lost this hormone-dependent regulatory function. Chimeric v-/c-erbA analysis mapped the loss-of-function to the very C-terminus of c-erbA, encompassing a cluster of conserved amino acids with the potential to form an amphipathic alpha-helix.","method":"Retroviral expression, chimeric protein analysis, erythroid differentiation assays, gene expression analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — systematic chimera mapping with defined phenotypic readout in physiologically relevant cell system","pmids":["1972036"],"is_preprint":false},{"year":1990,"finding":"The v-erbA protein specifically suppresses transcription of the avian erythrocyte anion transporter (band 3) gene at the transcriptional level, establishing band 3 as a direct transcriptional target of v-erbA/TRα. This repression correlates with, and contributes to, the differentiation block caused by v-erbA.","method":"Retroviral expression, transcription assays, alkaline pH rescue experiment, pharmacological inhibition of band 3","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection with multiple interventions (pH manipulation, inhibitor) and defined transcriptional readout","pmids":["2830979"],"is_preprint":false},{"year":1990,"finding":"In S. cerevisiae, the v-erbA protein unexpectedly acts as a hormone-regulated transcriptional activator rather than a repressor, demonstrating that the repressor activity of v-erbA in animal cells requires interaction with, or modification by, specific cellular factors absent in yeast. This establishes that TRα/v-erbA transcriptional activity is determined by cellular context.","method":"Yeast transcriptional activation assay, hormone treatment, cross-species comparison","journal":"Cell","confidence":"Medium","confidence_rationale":"Tier 2 — clean yeast system revealing context-dependence; single lab, single method","pmids":["1979758"],"is_preprint":false},{"year":1991,"finding":"The human THRA gene (c-erbA-1) is organized in 10 exons spanning ~27 kb on chromosome 17. Each zinc finger of the DNA-binding domain is encoded by a separate exon; the hormone-binding domain is assembled from three exons. The last two exons are alternatively spliced to generate TRα1 and TRα2 mRNAs. The genomic locus also encodes the oppositely transcribed ear-1/Rev-ErbA.","method":"Genomic DNA cloning, restriction mapping, exon sequencing, comparison with chicken gene","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 — direct genomic structural determination by sequencing","pmids":["1850510"],"is_preprint":false},{"year":1991,"finding":"A 269-bp complementary RNA (antisense to c-erbA alpha-2 mRNA), representing the 3' end of Rev-ErbA alpha mRNA, inhibits splicing of alpha-2 pre-mRNA in vitro, demonstrating that antisense RNA base-pairing can regulate alternative splicing of the Thra locus to favor formation of alpha-1 (TRα1) over alpha-2 mRNA.","method":"In vitro splicing assay with added antisense RNA, competition with sense/antisense controls","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro splicing with mechanistic dissection using complementary/non-complementary RNAs","pmids":["1657988"],"is_preprint":false},{"year":1991,"finding":"v-erbA overexpression is required to extinguish c-erbA (TRα) function in erythroid cells. When v-erbA and c-erbA are coexpressed at approximately equimolar levels, c-erbA activity is dominant: T3 induces erythroid differentiation and activates CAII transcription via a direct erbA-binding site in the CAII promoter. Very high v-erbA concentrations are required to suppress c-erbA-dependent activation.","method":"Stable co-expression in erythroblasts, T3 treatment, reporter gene assays with CAII erbA-binding site, differentiation assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — quantitative competition analysis in stably transformed cells with defined promoter element","pmids":["1682217"],"is_preprint":false},{"year":1991,"finding":"A single point mutation in the DNA-binding zinc finger domain differentiates v-erbA from c-erbA (TRα): back-mutation of this viral residue to the c-erbA sequence severely impairs erythroid transformation and produces subtle changes in DNA binding, indicating that altered DNA-binding specificity contributes to v-erbA oncogenic activation.","method":"Site-directed mutagenesis (back-mutation), erythroid transformation assay, EMSA/DNA binding assay","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis with functional phenotypic readout; single lab","pmids":["1672166"],"is_preprint":false},{"year":1991,"finding":"c-erbA alpha (TRα) and retinoic acid receptor alpha (RARα) cooperate in modulating normal erythroid differentiation. T3 and retinoic acid act synergistically, and the receptor dimerization domain of TRα is required for this functional cooperation, suggesting TRα/RARα heterodimers regulate erythroid differentiation.","method":"Primary erythroid progenitor culture, ligand treatment, retroviral receptor overexpression, genetic analysis with dimerization-domain mutants","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis with dimerization-domain mutant implicating heterodimerization; single lab","pmids":["1347914"],"is_preprint":false},{"year":1992,"finding":"Retinoid X receptor alpha (RXRα) is a required dimerization partner for thyroid hormone receptor (TRα) for stable DNA binding. RXRα co-purifies with TRα, forms heterodimers in solution, and greatly enhances TRα transcriptional activity. TRα is a monomer in solution and cannot form stable homodimeric complexes on response elements without RXRα.","method":"Biochemical co-purification, solution binding assays, EMSA, co-transfection reporter assays","journal":"Nature / The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — biochemical reconstitution with co-purification and EMSA; replicated independently (PMIDs 1310350, 1314167)","pmids":["1310350","1314167"],"is_preprint":false},{"year":1993,"finding":"A conserved 9-amino acid sequence at the extreme carboxy terminus of c-ErbA alpha (TRα), which is deleted in v-ErbA, is essential for T3-dependent transcriptional activation, AP-1 interference, and induction of erythroid differentiation. Single, double, and triple amino acid substitutions within this region abolish all these activities and reduce T3 binding, but a chimera with similarly reduced T3 binding retains function, showing the C-terminal domain has a role beyond just hormone binding.","method":"c-ErbA/v-ErbA chimera analysis, site-directed mutagenesis, reporter assays, differentiation assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis with multiple mutants and multiple orthogonal functional readouts","pmids":["8098843"],"is_preprint":false},{"year":1993,"finding":"c-ErbA alpha (TRα) can act as a ligand-independent transcriptional activator through a novel RSV-T3RE response element, distinct from classical T3REs. This activation utilizes a unique N-terminal activation domain and involves either TRα homodimers or TRα/RXR heterodimers. Ligand (T3) reverses activation through this element. DNA binding to the RSV-T3RE induces a different TRα conformation than binding to classical T3REs, demonstrating response-element-directed selective deployment of activation domains.","method":"Transient transfection reporter assays, RXR co-transfection, deletion mutagenesis of activation domains","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — systematic domain dissection with multiple deletion mutants, defined response elements, and heterodimerization analysis","pmids":["7903219"],"is_preprint":false},{"year":1993,"finding":"c-erbA alpha (TRα) and v-erbA both enhance c-Jun transcriptional activation in certain promoter contexts, acting as co-activators of AP-1. This reveals a positive transcriptional function for TRα/v-erbA through cooperative interaction with c-Jun, distinct from their repressor activities.","method":"Transient co-transfection reporter assays with c-Jun, c-Fos, c-erbA, v-erbA","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 3 — single lab, transient co-transfection; no direct protein-protein interaction demonstrated","pmids":["1349165"],"is_preprint":false},{"year":1993,"finding":"c-erbA alpha (TRα) promoter is a TATA-less, GC-rich promoter containing multiple Sp1 sites. Glucocorticoid (dexamethasone) enhances THRA promoter activity, but thyroid hormone does not, establishing autoregulation of THRA gene expression is not mediated via its own promoter.","method":"Transfection of CAT reporter constructs driven by human THRA promoter, hormone treatment of HeLa cells","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — direct promoter functional characterization with defined hormone treatments","pmids":["8455948"],"is_preprint":false},{"year":1993,"finding":"Stable expression of unliganded c-erbA alpha (TRα1) in mouse neuroblastoma N2a cells induces trkB mRNA expression and protein (gp145trkB) that is phosphorylated on tyrosine in response to BDNF, while concomitantly suppressing trkA and trkC. This TRα1-driven trkB induction is ligand-independent and is also produced by transient expression of TRβ1, indicating a conserved function of unliganded TR in regulating neurotrophin receptor expression.","method":"Stable transfection, Northern blot, Western blot, tyrosine phosphorylation assay, BDNF stimulation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — stable expression with defined molecular readout (trkB induction and functional phosphorylation); single lab","pmids":["8134111"],"is_preprint":false},{"year":1993,"finding":"v-erbA oncogenic function in neoplasia best correlates not with suppression of c-erbA/TRα action but with its ability to interfere with retinoic acid receptor (RAR) signaling. v-erbA forms heterodimers with RXR, which dramatically interferes with RXR transcriptional activity. In contrast, v-erbA interferes with thyroid hormone and trans-retinoic acid receptors by competing for DNA response elements, without observable heterodimerization.","method":"Co-transfection reporter assays, EMSA for heterodimerization, correlation of transformation with receptor interference","journal":"Cell / Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection with EMSA, reporter assays, and multiple receptor combinations; replicated across two studies","pmids":["1679679","8105369"],"is_preprint":false},{"year":1993,"finding":"Unliganded TRα (c-erbA), but not v-erbA, suppresses RAR-dependent transactivation by titrating out the common dimerization partner RXR. TRα competes with RAR for RXR and dissociates preformed RAR/RXR-RARE complexes in vitro. A single point mutation in the TRα dimerization interface (equivalent to the v-erbA Pro349 position) abolishes this trans-dominant suppression, demonstrating that RXR competition is the mechanism.","method":"Co-transfection reporter assays, in vitro EMSA competition, site-directed mutagenesis of dimerization domain","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution of complex dissociation plus mutagenesis plus cell-based validation","pmids":["8096810"],"is_preprint":false},{"year":1994,"finding":"c-erbA alpha (TRα) and RARα control commitment of hematopoietic self-renewing progenitor cells to apoptosis or differentiation; both T3 and RA induce apoptosis and strong inhibition of self-renewal in progenitor cells. The v-erbA oncogene renders erythrocytic progenitor cells insensitive to apoptosis and self-renewal inhibition induced by RA or T3, through its transforming activity.","method":"Normal erythrocytic progenitor culture, ligand treatment, apoptosis and self-renewal assays, v-erbA retroviral expression","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — primary cell culture with defined ligand treatments and loss-of-function v-erbA; single lab","pmids":["7906409"],"is_preprint":false},{"year":1994,"finding":"TRα (c-erbA alpha/TR alpha-1) expressed in the adrenal medulla progenitor cell line PC12 inhibits NGF-induced neuronal differentiation and represses neuron-specific gene expression in the absence of T3, while permitting normal differentiation in the presence of T3. In the absence of T3, TRα-expressing cells become NGF-responsive for proliferation. TRα also constitutively blocks dexamethasone-induced chromaffin differentiation, revealing a role for TRα in controlling progenitor commitment.","method":"Stable retroviral expression of TRα in PC12 cells, NGF and T3 treatment, differentiation and gene expression assays","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — stable expression system with defined ligand conditions and multiple differentiation readouts; single lab","pmids":["8385673"],"is_preprint":false},{"year":1994,"finding":"v-erbA binds as homodimers to thyroid hormone response elements (TREs), and forms heterodimers with RXR, T3 receptor auxiliary protein (TRAP), and TRα. High concentrations of T3 decrease v-erbA homodimer binding to TREs. Multiple v-erbA complexes (homodimers, heterodimers with RXR/TRAP/TRα) all remain bound to DNA in the presence of T3 and can compete with TR-containing complexes, contributing to dominant negative effects.","method":"EMSA with in vitro translated proteins, co-transfection reporter assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — direct EMSA characterization of multiple complex types; single lab","pmids":["7904604"],"is_preprint":false},{"year":1994,"finding":"c-ErbA (TRα) but not v-ErbA forms heterodimers with RXR that compete with the erythrocyte-specific nuclear factor NFX for binding to the CAII promoter PAL2 site. This competition displaces the repressor NFX, providing a mechanism by which T3-activated TRα/RXR activates CAII transcription. v-ErbA alone or with RXR fails to compete with NFX, explaining why v-ErbA cannot activate CAII.","method":"EMSA competition assays, transfection reporter assays, identification of NFX erythrocyte-specific factor","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — EMSA competition with defined factors; single lab","pmids":["7916146"],"is_preprint":false},{"year":1995,"finding":"A nuclear receptor co-repressor (N-CoR) of ~270 kDa physically interacts with thyroid hormone receptor (TRα) and mediates ligand-independent transcriptional repression. N-CoR association with TR is destabilized by T3, providing a molecular mechanism for unliganded TR repression and ligand-induced de-repression.","method":"Biochemical purification, co-immunoprecipitation, in vitro protein binding, reporter gene assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — biochemical identification and purification of corepressor with functional validation; replicated independently (PMIDs 7566114, 7566127)","pmids":["7566114","7566127"],"is_preprint":false},{"year":1995,"finding":"SMRT (silencing mediator for retinoid and thyroid-hormone receptors) was identified as a corepressor that interacts with thyroid hormone receptor (TRα) in solution and when bound to DNA response elements. This association is destabilized by ligand. In vivo SMRT functions as a potent corepressor of TR-mediated transcription.","method":"Protein interaction screen, co-immunoprecipitation, reporter assays, GAL4 fusion repressor assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — direct biochemical interaction and functional demonstration; independent identification alongside N-CoR","pmids":["7566127"],"is_preprint":false},{"year":1995,"finding":"Two classes of TR-interacting proteins (TRIPs) were identified by yeast interaction trap: one class interacts with TRβ ligand-binding domain only in the presence of T3 (putative coactivators), another only in its absence (putative corepressors). Neither class interacts with glucocorticoid receptor. Trip4 contains a transcriptional activation domain; Trip9/10 confer indirect T3-dependent activation when co-expressed with TR and RXR in yeast.","method":"Yeast interaction trap, in vitro binding, yeast reporter assays","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — yeast two-hybrid with functional validation; identifies ligand-dependent interaction classes","pmids":["7776974"],"is_preprint":false},{"year":1996,"finding":"CBP (CREB-binding protein) directly interacts with the ligand-binding domain of multiple nuclear receptors including TRα, and this interaction is required for ligand-dependent transcriptional activation. CBP also interacts with p160 coactivators (SRC-1 variants). Competition between nuclear receptors and AP-1 for limiting amounts of CBP/p300 underlies AP-1 inhibition by TRα.","method":"Direct protein interaction assays, co-immunoprecipitation, reporter assays, dominant negative CBP competition","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — direct interaction demonstrated with multiple orthogonal methods; competition mechanism functionally validated","pmids":["8616895"],"is_preprint":false},{"year":1996,"finding":"TRα purified from HeLa cells grown in the presence of T3 is associated with a group of nuclear proteins termed thyroid hormone receptor-associated proteins (TRAPs), forming a ligand-induced multisubunit coactivator complex. This TR/TRAP complex markedly activates transcription from T3-responsive promoters in cell-free assays. TRα purified without T3 lacks TRAPs and shows only low-level, ligand-dependent activation. RXR is required for TRAP complex function but is not a TRAP component.","method":"Biochemical purification from HeLa cells, in vitro transcription reconstitution, T3-dependent complex assembly","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — biochemical purification and cell-free reconstituted transcription; ligand-dependence directly demonstrated","pmids":["8710870"],"is_preprint":false},{"year":1996,"finding":"SHP (short heterodimer partner), an orphan nuclear receptor lacking a DNA-binding domain, interacts directly with the thyroid hormone receptor (TRα) via its ligand-binding/dimerization domain in yeast two-hybrid and in vitro binding assays. SHP specifically inhibits TR-dependent transactivation in mammalian cells, functioning as a negative regulator of TR signaling.","method":"Yeast two-hybrid, in vitro binding assay, co-transfection reporter assay","journal":"Science","confidence":"Medium","confidence_rationale":"Tier 2 — two independent methods (yeast two-hybrid + in vitro binding) with functional validation; single lab","pmids":["8650544"],"is_preprint":false},{"year":1997,"finding":"ACTR, a nuclear receptor coactivator, directly binds TRα (and other nuclear receptors) in a hormone-dependent manner and recruits CBP and P/CAF to form a multisubunit coactivator complex. ACTR itself possesses intrinsic histone acetyltransferase (HAT) activity, establishing that TRα activation involves coordinated HAT activity from at least three enzymes (ACTR, CBP, P/CAF).","method":"Direct protein binding assays, co-immunoprecipitation, in vitro HAT assay with purified ACTR","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — purified protein HAT assay plus multi-component complex reconstitution","pmids":["9267036"],"is_preprint":false},{"year":1997,"finding":"v-ErbA can substitute for the ligand-activated glucocorticoid receptor (GR) and estrogen receptor (ER) to induce proliferation and arrest differentiation of erythroid progenitors, and requires cooperation with c-Kit (receptor tyrosine kinase) for both activities. v-ErbA's biological activities depend on distinct mutations in the DNA-binding domain. v-ErbA acts as a weak, partial repressor of c-ErbA/TRα function (not fully dominant negative) in normal erythroblasts; full dominant-negative activity requires restoration of RXR heterodimerization capacity.","method":"Retroviral expression in erythroid progenitors, GR/ER antagonist treatment, c-Kit dependency analysis, RXR heterodimerization mutant rescue","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — genetic dissection of v-erbA mechanisms in primary progenitor cells; single lab","pmids":["9264411"],"is_preprint":false},{"year":1998,"finding":"TRAP220, a component of the TRAP coactivator complex, directly interacts with TRα (and other nuclear receptors) in a ligand-dependent manner through its LXXLL motifs engaging the C-terminus of TRα. A fragment containing LXXLL motifs acts as a dominant negative inhibitor of nuclear receptor-mediated transcription. TRAP220 plays a central role in anchoring other TRAPs to TRα.","method":"Co-immunoprecipitation, direct binding assays, transfection reporter assays, cell-free transcription assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — direct binding with defined motifs, cell-free transcription reconstitution, dominant negative validation","pmids":["9653119"],"is_preprint":false},{"year":1998,"finding":"NSD1, a novel nuclear protein with SET domain and PHD fingers, contains two distinct TR interaction domains (NID-L and NID+L) with opposing properties: NID-L interacts with unliganded TRα LBD (requiring helix 1 integrity, like corepressors), while NID+L interacts with liganded TRα LBD (requiring helix 12, like coactivators). NSD1 contains both repression and activation domains, functioning as a bifunctional transcriptional intermediary factor.","method":"Yeast two-hybrid, in vitro pull-down with defined LBD mutants, transient transfection reporter assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 — systematic mutagenesis of both receptor and cofactor with multiple interaction assays demonstrating mechanistic basis","pmids":["9628876"],"is_preprint":false},{"year":1998,"finding":"v-ErbA constitutively binds to the carbonic anhydrase II (CAII) gene intronic erythroid enhancer element (HS2-VRE) in vivo in transformed undifferentiated erythroblasts, as shown by in vivo footprinting. This binding co-occurs with GATA-1. Treatment with histone deacetylase inhibitor trichostatin A derepresses the chromatin-embedded endogenous CAII gene but not a transfected construct, demonstrating that HDAC activity is required for v-ErbA repression at the endogenous chromatin-embedded locus.","method":"In vivo footprinting, retroviral expression assays, trichostatin A treatment, transfection assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — in vivo footprinting directly demonstrates receptor-chromatin binding; pharmacological dissection of HDAC requirement","pmids":["9857194"],"is_preprint":false},{"year":1999,"finding":"The TRAP complex (thyroid hormone receptor-associated proteins) is virtually identical to the SMCC (SRB- and MED-containing cofactor complex) that mediates transcriptional activation by p53. TRAP80 directly interacts with p53 and VP16 activation domains. The TRAP220/SMCC220 subunit binds liganded TRα. This establishes that TRα and other activators share a common coactivator complex targeting RNA Pol II.","method":"Mass spectrometry of purified complexes, direct protein binding assays, reporter assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — mass spectrometry identification combined with direct protein interaction and functional data","pmids":["10198638"],"is_preprint":false},{"year":1999,"finding":"Ligand-dependent activation by TRα requires the DRIP complex (distinct from TRAP only by nomenclature in context of VDR). The DRIP complex mediates ligand-dependent enhancement of transcription by TRα in cell-free transcription assays on chromatin templates, establishing DRIPs as positive coactivators for TRα.","method":"Cell-free transcription assay on chromatin templates, biochemical purification of DRIP complex","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — cell-free reconstitution on chromatin templates with purified complex","pmids":["10235266"],"is_preprint":false},{"year":2000,"finding":"v-ErbA and TRα both recruit N-CoR and concomitantly HDAC3 (without association with Sin3, HDAC1/RPD3, Mi-2, or HDAC5) on thyroid hormone-responsive templates in Xenopus oocytes. v-ErbA repression is more HDAC-inhibitor sensitive than TRα repression and requires mature chromatin (v-ErbA cannot repress on partly chromatinized templates). v-ErbA is less competent than TRα for binding TFIIB in vitro and in vivo, explaining reduced repression on non-chromatinized templates.","method":"Xenopus oocyte injection, chromatin immunoprecipitation, HDAC inhibitor treatment, in vitro TFIIB binding assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — in vivo chromatin assay in oocytes, ChIP, in vitro binding, pharmacological dissection; multiple orthogonal methods","pmids":["10921888"],"is_preprint":false},{"year":2001,"finding":"A targeted mutation (Thra(tm2)) in the mouse Thra gene that deletes TRα2 and causes overexpression of TRα1 suppresses deafness and thyroid hyperactivity phenotypes caused by Thrb-null mutation. This demonstrates that increased TRα1 expression can functionally substitute for TRβ in auditory and thyroid functions, revealing significant functional overlap between TR isotypes.","method":"Mouse genetics (targeted deletion), auditory threshold testing, thyroid function assays, genetic epistasis in double-mutant mice","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — clean genetic epistasis in mouse model with multiple quantitative phenotypic readouts","pmids":["11726557"],"is_preprint":false},{"year":2005,"finding":"v-ErbA dimerizes with TRα and RXR and sequesters a significant fraction of both nuclear receptors in the cytoplasm, partially reversing their normal nuclear localization. Ligand and histone deacetylase inhibitor (trichostatin A) partially restore TRα nuclear localization. This defines cytoplasmic sequestration as an additional dominant-negative mechanism for v-ErbA distinct from DNA competition.","method":"Subcellular fractionation, co-immunoprecipitation, immunofluorescence microscopy, histone deacetylase inhibitor treatment","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization with fractionation and imaging, co-IP for dimerization; single lab","pmids":["15650025"],"is_preprint":false},{"year":2009,"finding":"T3 activates PI3-kinase via Src kinase signaling through an αvβ3 integrin receptor, and PI3-kinase activity mediates shuttling of nuclear TRα from cytoplasm to nucleus. LY-294002 (PI3-kinase inhibitor) blocks T3-induced TRα nuclear translocation and HIF-1α mRNA accumulation. This establishes a non-genomic T3 signaling pathway regulating TRα subcellular localization.","method":"PI3-kinase inhibitor treatment, siRNA knockdown of PI3-kinase, subcellular localization assays, integrin antagonist experiments","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological and siRNA validation of PI3-kinase requirement for TRα trafficking; single lab","pmids":["19158403"],"is_preprint":false},{"year":2015,"finding":"Truncating and missense mutations in the THRA gene cause resistance to thyroid hormone alpha (RTHα) with a consistent phenotype including growth retardation, macrocephaly, skeletal dysplasia, mental retardation, low fT4/high fT3 ratio, and anemia. A genotype-phenotype correlation was established: truncating mutations cause more severe phenotypes than missense mutations. Whole exome sequencing identified THRA as the causative gene.","method":"Whole exome sequencing, Sanger sequencing confirmation, clinical/biochemical characterization of 6 patients from 5 families","journal":"Journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 3 — genotype-phenotype correlation in human patients; molecular mechanism inferred from mutation type","pmids":["25670821"],"is_preprint":false},{"year":2015,"finding":"A de novo missense mutation in THRA (N359Y) affecting TRα1 causes RTHα with severe bone malformation, dwarfism, and macrocytic anemia. The mutant TRα1(N359Y) has decreased T3 binding affinity and dominant-negative effect on wild-type TRα1 in transcriptional assays, with low resting energy expenditure normalized by T3 treatment.","method":"Whole exome sequencing, in vitro transcription assay, T3 binding assay, clinical T3 treatment trial","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 — functional characterization of mutant receptor in vitro with clinical correlation; single case","pmids":["26037512"],"is_preprint":false},{"year":2018,"finding":"CRISPR/Cas9 editing of the mouse Thra gene producing frameshift or missense mutations recapitulates human RTHα with variable phenotype severity. Phenotype severity correlates with the ability of the mutant TRα1 to interact with transcriptional corepressors in the presence of thyroid hormone (i.e., corepressor release by T3 is impaired in proportion to severity).","method":"CRISPR/Cas9 genome editing, mouse phenotypic analysis, corepressor interaction assay in presence/absence of T3","journal":"Thyroid","confidence":"High","confidence_rationale":"Tier 2 — genetic models with multiple alleles, phenotypic characterization, and defined molecular mechanism (corepressor release)","pmids":["29205102"],"is_preprint":false},{"year":2019,"finding":"THRA missense mutations M259T and T273A in RTHα patients reduce TRα1 affinity for T3, such that corepressors fail to dissociate from the mutant receptor even in the presence of T3. In silico modeling combined with T3 binding assays and corepressor interaction assays demonstrates that the severity of RTHα correlates with reduction in T3 binding affinity and the consequent inability to release corepressors.","method":"Biochemical T3 binding assays, corepressor interaction assays, in silico structural modeling, cellular transcriptional assays","journal":"Thyroid","confidence":"Medium","confidence_rationale":"Tier 2 — multiple biochemical methods with structural modeling; small patient series","pmids":["32204686"],"is_preprint":false}],"current_model":"THRA encodes thyroid hormone receptor alpha (TRα), a ligand-dependent nuclear transcription factor that, when unliganded, recruits corepressors (N-CoR, SMRT) and HDAC3 to silence target genes, and upon T3 binding releases corepressors and assembles a multisubunit coactivator complex (TRAP/DRIP containing CBP, ACTR, TRAP220/MED1, and related HATs) via its conserved C-terminal AF-2 helix—functioning primarily as RXRα heterodimers on direct-repeat response elements; phosphorylation by CK2 (Ser12) and PKA/PKC (Ser28/29) modulates its activity; alternative splicing generates a non-T3-binding TRα2 isoform that acts as a dominant inhibitor of TRα1; and loss-of-function THRA mutations that impair T3 binding or corepressor release cause resistance to thyroid hormone alpha (RTHα) with growth retardation, skeletal dysplasia, and macrocephaly."},"narrative":{"teleology":[{"year":1986,"claim":"Identification of c-erbA as a high-affinity T3/T4 receptor established that a known proto-oncogene is a nuclear hormone receptor, resolving the molecular identity of the thyroid hormone receptor.","evidence":"Hormone binding assays and nuclear localization studies comparing c-erbA and v-erbA proteins","pmids":["2879242","2879243"],"confidence":"High","gaps":["No information on DNA target specificity","Structure of the receptor unknown","Mechanism of transcriptional regulation not addressed"]},{"year":1988,"claim":"Discovery of alternative splicing generating TRα2 (non-T3-binding) and identification of PKA/CK2 phosphorylation sites revealed two major regulatory axes—isoform diversity and post-translational modification—that modulate TRα function independently of ligand.","evidence":"cDNA cloning and in vitro T3 binding showing TRα2 lacks hormone binding; tryptic phosphopeptide mapping and in vitro kinase assays with purified PKA and CK2 identifying Ser12 and Ser28/29","pmids":["2537467","2903825","2552374"],"confidence":"High","gaps":["Functional consequence of phosphorylation on transcriptional activity not determined","Physiological role of TRα2 in vivo unknown","No structural basis for why TRα2 cannot bind T3"]},{"year":1989,"claim":"Mapping the C-terminal activation domain and demonstrating that unliganded TRα is a transcriptional repressor (while T3 converts it to an activator) established the dual-function switch model and defined the functional importance of the AF-2 helix region.","evidence":"Chimeric v-erbA/c-erbA protein analysis, co-transfection reporter assays, and erythroid differentiation assays","pmids":["2733791","8098843","1972036"],"confidence":"High","gaps":["No cofactors identified that mediate repression or activation","No structural model of the AF-2 region","Mechanism of AP-1 interference unclear"]},{"year":1992,"claim":"Demonstration that RXRα is the obligate heterodimerization partner for stable TRα DNA binding and transcriptional activity resolved how TRα engages response elements and explained why unliganded TRα can sequester RXR from RAR, suppressing retinoic acid signaling.","evidence":"Biochemical co-purification, EMSA, co-transfection reporter assays, and mutagenesis of the dimerization interface","pmids":["1310350","1314167","8096810"],"confidence":"High","gaps":["Crystal structure of TRα/RXR heterodimer not available","In vivo relevance of RXR competition with RAR not established in genetic models"]},{"year":1995,"claim":"Identification of N-CoR and SMRT as corepressors that bind unliganded TRα and are released upon T3 binding provided the molecular basis for the repression-to-activation switch.","evidence":"Biochemical purification, co-immunoprecipitation, in vitro binding, and reporter gene assays","pmids":["7566114","7566127"],"confidence":"High","gaps":["Chromatin context of corepressor recruitment not yet examined","Identity of the histone-modifying activity in the corepressor complex unknown"]},{"year":1996,"claim":"Purification of the TRAP coactivator complex from T3-treated cells and demonstration of CBP recruitment established that ligand-activated TRα assembles a multisubunit coactivator platform linking to general transcription machinery.","evidence":"Biochemical purification from HeLa cells, cell-free transcription assays on T3-responsive promoters, direct interaction assays for CBP","pmids":["8710870","8616895"],"confidence":"High","gaps":["Subunit composition of TRAP complex not fully resolved","Sequential versus simultaneous coactivator recruitment not distinguished"]},{"year":1998,"claim":"Identification of TRAP220/MED1 as the LXXLL-motif-containing anchor subunit for TR, and of ACTR as a HAT-containing coactivator, completed the picture of a coordinated multi-HAT coactivator assembly (ACTR + CBP + P/CAF) recruited to TRα via TRAP220.","evidence":"Direct binding assays with LXXLL motif mutants, dominant negative TRAP220 fragments, purified ACTR HAT assays, cell-free transcription","pmids":["9653119","9267036"],"confidence":"High","gaps":["Order of coactivator recruitment to endogenous chromatin not defined","No genome-wide map of TRα-occupied enhancers"]},{"year":2000,"claim":"ChIP-based demonstration that TRα and v-erbA recruit N-CoR with HDAC3 (excluding Sin3, HDAC1, Mi-2) on chromatinized templates in vivo defined the specific HDAC complex used for TRα-mediated repression.","evidence":"Xenopus oocyte ChIP, HDAC inhibitor treatment, in vitro TFIIB binding assays","pmids":["10921888"],"confidence":"High","gaps":["Whether the same N-CoR/HDAC3 complex operates at mammalian endogenous loci not confirmed","No structural basis for selective HDAC3 recruitment over other HDACs"]},{"year":2015,"claim":"Discovery that loss-of-function THRA mutations cause resistance to thyroid hormone alpha (RTHα) in humans linked the molecular mechanism of impaired T3 binding and corepressor release to a defined clinical syndrome of growth retardation, skeletal dysplasia, and macrocephaly.","evidence":"Whole exome sequencing in patient cohorts, in vitro T3 binding and transcriptional assays of mutant TRα1","pmids":["25670821","26037512"],"confidence":"Medium","gaps":["Small patient numbers limit genotype-phenotype generalization","Tissue-specific consequences of mutations not dissected","No rescue experiments in patient-derived cells"]},{"year":2018,"claim":"CRISPR-generated mouse models established that RTHα phenotype severity correlates directly with the degree to which mutant TRα1 retains corepressor binding in the presence of T3, providing a unifying mechanistic explanation for genotype-phenotype variability.","evidence":"CRISPR/Cas9 editing of mouse Thra with multiple alleles, phenotypic analysis, corepressor interaction assays ± T3","pmids":["29205102"],"confidence":"High","gaps":["Whether pharmacological corepressor displacement can rescue phenotypes not tested","Contribution of non-genomic TRα signaling to RTHα phenotype unknown"]},{"year":null,"claim":"The genome-wide chromatin landscape of TRα1 occupancy, the structural basis of isoform-specific coactivator/corepressor selectivity, and the physiological role of TRα2 in vivo remain incompletely resolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No genome-wide ChIP-seq map of endogenous TRα1 binding in key tissues","TRα2 knockout phenotype not fully characterized","Structural basis for HDAC3-selective recruitment unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,5,6,8,20,21]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,4,19,21]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,41,46,47]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[6,8,20,21,31,35,37]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,9,47]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[11,27,28,45]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[48,49,50]}],"complexes":["TRAP/Mediator complex","TRα/RXRα heterodimer","N-CoR/SMRT/HDAC3 corepressor complex"],"partners":["RXRA","NCOR1","NCOR2","HDAC3","MED1","NCOA3","CREBBP","NR0B2"],"other_free_text":[]},"mechanistic_narrative":"THRA encodes thyroid hormone receptor alpha (TRα), a ligand-dependent nuclear transcription factor that functions primarily as an RXRα heterodimer on direct-repeat thyroid hormone response elements to control programs of erythroid, neuronal, and skeletal differentiation [PMID:1310350, PMID:8385673, PMID:1972036]. In the unliganded state, TRα recruits the corepressors N-CoR and SMRT together with HDAC3 to silence target genes; T3 binding triggers corepressor release and assembly of a multisubunit coactivator complex (TRAP/DRIP–Mediator) anchored by TRAP220/MED1 via LXXLL motifs, with additional recruitment of CBP, ACTR, and P/CAF providing coordinated histone acetyltransferase activity [PMID:7566114, PMID:8710870, PMID:9653119, PMID:9267036]. Alternative splicing generates TRα2, a non-T3-binding isoform that acts as a dominant inhibitor of TRα1, and phosphorylation by CK2 (Ser12) and PKA/PKC (Ser28/29) further modulates receptor activity [PMID:2537467, PMID:2552374, PMID:2903825]. Loss-of-function THRA mutations that reduce T3 binding affinity and impair corepressor release cause resistance to thyroid hormone alpha (RTHα), characterized by growth retardation, skeletal dysplasia, macrocephaly, and anemia [PMID:25670821, PMID:29205102]."},"prefetch_data":{"uniprot":{"accession":"P10827","full_name":"Thyroid hormone receptor alpha","aliases":["Nuclear receptor subfamily 1 group A member 1","V-erbA-related protein 7","EAR-7","c-erbA-1","c-erbA-alpha"],"length_aa":490,"mass_kda":54.8,"function":"Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine Does not bind thyroid hormone and functions as a weak dominant negative inhibitor of thyroid hormone action","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P10827/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/THRA","classification":"Not Classified","n_dependent_lines":22,"n_total_lines":1208,"dependency_fraction":0.018211920529801324},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/THRA","total_profiled":1310},"omim":[{"mim_id":"616223","title":"ANGIOPOIETIN-LIKE 8; ANGPTL8","url":"https://www.omim.org/entry/616223"},{"mim_id":"615354","title":"LIGAND-DEPENDENT NUCLEAR RECEPTOR-INTERACTING FACTOR 1; LRIF1","url":"https://www.omim.org/entry/615354"},{"mim_id":"614450","title":"HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 6; CHNG6","url":"https://www.omim.org/entry/614450"},{"mim_id":"612054","title":"CCR4-NOT TRANSCRIPTION COMPLEX, SUBUNIT 9; CNOT9","url":"https://www.omim.org/entry/612054"},{"mim_id":"611583","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 5A; ARID5A","url":"https://www.omim.org/entry/611583"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Cytosol","reliability":"Uncertain"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":400.8}],"url":"https://www.proteinatlas.org/search/THRA"},"hgnc":{"alias_symbol":["EAR-7.1/EAR-7.2","THRA3","AR7","ERBA","NR1A1","TRalpha","TRalpha1","TRalpha2","c-ERBA-1","c-erbA","THRalpha","THRalpha1","THRalpha2"],"prev_symbol":["THRA1","THRA2","ERBA1"]},"alphafold":{"accession":"P10827","domains":[{"cath_id":"3.30.50.10","chopping":"42-127","consensus_level":"medium","plddt":94.6478,"start":42,"end":127},{"cath_id":"1.10.565.10","chopping":"161-385_398-406","consensus_level":"high","plddt":84.8458,"start":161,"end":406}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P10827","model_url":"https://alphafold.ebi.ac.uk/files/AF-P10827-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P10827-F1-predicted_aligned_error_v6.png","plddt_mean":73.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=THRA","jax_strain_url":"https://www.jax.org/strain/search?query=THRA"},"sequence":{"accession":"P10827","fasta_url":"https://rest.uniprot.org/uniprotkb/P10827.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P10827/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P10827"}},"corpus_meta":[{"pmid":"3755102","id":"PMC_3755102","title":"The chicken oestrogen receptor sequence: homology with v-erbA and the human oestrogen and glucocorticoid receptors.","date":"1986","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/3755102","citation_count":645,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2733791","id":"PMC_2733791","title":"Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist.","date":"1989","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2733791","citation_count":616,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2537467","id":"PMC_2537467","title":"Inhibition of thyroid hormone action by a non-hormone binding c-erbA protein generated by alternative mRNA splicing.","date":"1989","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2537467","citation_count":433,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3299059","id":"PMC_3299059","title":"Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene.","date":"1987","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3299059","citation_count":368,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2901090","id":"PMC_2901090","title":"Alternative splicing generates messages encoding rat c-erbA proteins that do not bind thyroid hormone.","date":"1988","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2901090","citation_count":312,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2542765","id":"PMC_2542765","title":"A novel member of the thyroid/steroid hormone receptor family is encoded by the opposite strand of the rat c-erbA alpha transcriptional unit.","date":"1989","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2542765","citation_count":309,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6297784","id":"PMC_6297784","title":"Transforming capacities of avian erythroblastosis virus mutants deleted in the erbA or erbB oncogenes.","date":"1983","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/6297784","citation_count":300,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3281095","id":"PMC_3281095","title":"Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue.","date":"1988","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/3281095","citation_count":284,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2162351","id":"PMC_2162351","title":"Relationship of c-erbA mRNA content to tissue triiodothyronine nuclear binding capacity and function in developing and adult rats.","date":"1990","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2162351","citation_count":283,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2903438","id":"PMC_2903438","title":"Identification of a rat c-erbA alpha-related protein which binds deoxyribonucleic acid but does not bind thyroid hormone.","date":"1988","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/2903438","citation_count":275,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2153150","id":"PMC_2153150","title":"Differential and tissue-specific regulation of the multiple rat c-erbA messenger RNA species by thyroid hormone.","date":"1990","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/2153150","citation_count":249,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2539258","id":"PMC_2539258","title":"Two erbA homologs encoding proteins with different T3 binding capacities are transcribed from opposite DNA strands of the same genetic locus.","date":"1989","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2539258","citation_count":244,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1972036","id":"PMC_1972036","title":"v-erbA oncogene activation entails the loss of hormone-dependent regulator activity of c-erbA.","date":"1990","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1972036","citation_count":240,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1661299","id":"PMC_1661299","title":"Characterization of seven novel mutations of the c-erbA beta gene in unrelated kindreds with generalized thyroid hormone resistance. Evidence for two \"hot spot\" regions of the ligand binding domain.","date":"1991","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/1661299","citation_count":234,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2905047","id":"PMC_2905047","title":"Identification of two novel members of erbA superfamily by molecular cloning: the gene products of the two are highly related to each other.","date":"1988","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2905047","citation_count":212,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8474464","id":"PMC_8474464","title":"The orphan receptor Rev-ErbA alpha activates transcription via a novel response element.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8474464","citation_count":208,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6323162","id":"PMC_6323162","title":"Chromosomal localisation of the human homologues to the oncogenes erbA and B.","date":"1984","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/6323162","citation_count":199,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1663215","id":"PMC_1663215","title":"Independent expression of the alpha and beta c-erbA genes in developing rat brain.","date":"1991","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/1663215","citation_count":194,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2153155","id":"PMC_2153155","title":"A base mutation of the C-erbA beta thyroid hormone receptor in a kindred with generalized thyroid hormone resistance. Molecular heterogeneity in two other kindreds.","date":"1990","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/2153155","citation_count":178,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2905763","id":"PMC_2905763","title":"Tight linkage between the syndrome of generalized thyroid hormone resistance and the human c-erbA beta gene.","date":"1988","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/2905763","citation_count":160,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1682056","id":"PMC_1682056","title":"A novel mechanism of action for v-ErbA: abrogation of the inactivation of transcription factor AP-1 by retinoic acid and thyroid hormone receptors.","date":"1991","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1682056","citation_count":159,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3009024","id":"PMC_3009024","title":"v-erbA cooperates with sarcoma oncogenes in leukemic cell transformation.","date":"1986","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/3009024","citation_count":159,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2830979","id":"PMC_2830979","title":"v-erbA specifically suppresses transcription of the avian erythrocyte anion transporter (band 3) gene.","date":"1988","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2830979","citation_count":157,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2903825","id":"PMC_2903825","title":"Activation of protein kinase C or cAMP-dependent protein kinase increases phosphorylation of the c-erbA-encoded thyroid hormone receptor and of the v-erbA-encoded protein.","date":"1988","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2903825","citation_count":155,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1657988","id":"PMC_1657988","title":"Inhibition of c-erbA mRNA splicing by a naturally occurring antisense RNA.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1657988","citation_count":149,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2903439","id":"PMC_2903439","title":"c-erbA protooncogenes mediate thyroid hormone-dependent and independent regulation of the rat growth hormone and prolactin genes.","date":"1988","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/2903439","citation_count":147,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6589608","id":"PMC_6589608","title":"A human c-erbA oncogene homologue is closely proximal to the chromosome 17 breakpoint in acute promyelocytic leukemia.","date":"1984","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/6589608","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2554288","id":"PMC_2554288","title":"Human carboxyl-terminal variant of alpha-type c-erbA inhibits trans-activation by thyroid hormone receptors without binding thyroid hormone.","date":"1989","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2554288","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3359993","id":"PMC_3359993","title":"Characterization of the hormone-binding domain of the chicken c-erbA/thyroid hormone receptor protein.","date":"1988","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/3359993","citation_count":127,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2573734","id":"PMC_2573734","title":"Presence of two members of c-erbA receptor gene family (c-erbA beta and c-erbA2) in smallest region of somatic homozygosity on chromosome 3p21-p25 in human breast carcinoma.","date":"1989","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/2573734","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7903219","id":"PMC_7903219","title":"A novel cis element mediating ligand-independent activation by c-ErbA: implications for hormonal regulation.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7903219","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1679679","id":"PMC_1679679","title":"v-erbA oncogene function in neoplasia correlates with its ability to repress retinoic acid receptor action.","date":"1991","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1679679","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2884040","id":"PMC_2884040","title":"Expression of the v-erbA oncogene in chicken embryo fibroblasts stimulates their proliferation in vitro and enhances tumor growth in vivo.","date":"1987","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2884040","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1850510","id":"PMC_1850510","title":"Genomic organization of the human thyroid hormone receptor alpha (c-erbA-1) gene.","date":"1991","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/1850510","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6328658","id":"PMC_6328658","title":"Sequencing the erbA gene of avian erythroblastosis virus reveals a new type of oncogene.","date":"1984","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/6328658","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8098843","id":"PMC_8098843","title":"A conserved C-terminal sequence that is deleted in v-ErbA is essential for the biological activities of c-ErbA (the thyroid hormone receptor).","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8098843","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12082618","id":"PMC_12082618","title":"Expression of thyroid hormone receptor/erbA genes is altered in human breast cancer.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12082618","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2568887","id":"PMC_2568887","title":"Expression of the v-erbA product, an altered nuclear hormone receptor, is sufficient to transform erythrocytic cells in vitro.","date":"1989","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2568887","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10704394","id":"PMC_10704394","title":"Increased cell death and delayed development in the cerebellum of mice lacking the rev-erbA(alpha) orphan receptor.","date":"2000","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10704394","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8096810","id":"PMC_8096810","title":"Unliganded T3R, but not its oncogenic variant, v-erbA, suppresses RAR-dependent transactivation by titrating out RXR.","date":"1993","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8096810","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1347914","id":"PMC_1347914","title":"Modulation of normal erythroid differentiation by the endogenous thyroid hormone and retinoic acid receptors: a possible target for v-erbA oncogene action.","date":"1992","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1347914","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2884103","id":"PMC_2884103","title":"A single point mutation in erbA restores the erythroid transforming potential of a mutant avian erythroblastosis virus (AEV) defective in both erbA and erbB oncogenes.","date":"1987","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/2884103","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1979040","id":"PMC_1979040","title":"Phosphorylation of the v-erbA protein is required for its function as an oncogene.","date":"1990","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/1979040","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1682217","id":"PMC_1682217","title":"v-erbA overexpression is required to extinguish c-erbA function in erythroid cell differentiation and regulation of the erbA target gene CAII.","date":"1991","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/1682217","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1979758","id":"PMC_1979758","title":"The viral erbA oncogene protein, a constitutive repressor in animal cells, is a hormone-regulated activator in yeast.","date":"1990","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1979758","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7003595","id":"PMC_7003595","title":"Nucleotide sequence of the thrA gene of Escherichia coli.","date":"1980","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7003595","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2552374","id":"PMC_2552374","title":"The c-erbA alpha-encoded thyroid hormone receptor is phosphorylated in its amino terminal domain by casein kinase II.","date":"1989","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/2552374","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2572268","id":"PMC_2572268","title":"c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.","date":"1989","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/2572268","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8948627","id":"PMC_8948627","title":"Two receptor interaction domains in the corepressor, N-CoR/RIP13, are required for an efficient interaction with Rev-erbA alpha and RVR: physical association is dependent on the E region of the orphan receptors.","date":"1996","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/8948627","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7910550","id":"PMC_7910550","title":"v-erbA and citral reduce the teratogenic effects of all-trans retinoic acid and retinol, respectively, in Xenopus embryogenesis.","date":"1993","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/7910550","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8385673","id":"PMC_8385673","title":"Thyroid hormone receptor/c-erbA: control of commitment and differentiation in the neuronal/chromaffin progenitor line PC12.","date":"1993","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8385673","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7925269","id":"PMC_7925269","title":"Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-erbA.","date":"1994","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/7925269","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2901667","id":"PMC_2901667","title":"Regulation of two c-erbA messenger ribonucleic acids in rat GH3 cells by thyroid hormone.","date":"1988","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/2901667","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25670821","id":"PMC_25670821","title":"Thyroid hormone resistance syndrome due to mutations in the thyroid hormone receptor α gene (THRA).","date":"2015","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25670821","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1846005","id":"PMC_1846005","title":"A new point mutation in the 3,5,3'-triiodothyronine-binding domain of the c-erbA beta thyroid hormone receptor is tightly linked to generalized thyroid hormone resistance.","date":"1991","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/1846005","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7906409","id":"PMC_7906409","title":"c-erbA alpha/T3R and RARs control commitment of hematopoietic self-renewing progenitor cells to apoptosis or differentiation and are antagonized by the v-erbA oncogene.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7906409","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10921888","id":"PMC_10921888","title":"Targeting of N-CoR and histone deacetylase 3 by the oncoprotein v-erbA yields a chromatin infrastructure-dependent transcriptional repression pathway.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10921888","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8105369","id":"PMC_8105369","title":"The erbA oncogene represses the actions of both retinoid X and retinoid A receptors but does so by distinct mechanisms.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8105369","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1354613","id":"PMC_1354613","title":"Transcriptional repression of band 3 and CAII in v-erbA transformed erythroblasts accounts for an important part of the leukaemic phenotype.","date":"1992","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/1354613","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10809233","id":"PMC_10809233","title":"Structure-function analysis of the Rev-erbA and RVR ligand-binding domains reveals a large hydrophobic surface that mediates corepressor binding and a ligand cavity occupied by side chains.","date":"2000","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/10809233","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1645454","id":"PMC_1645454","title":"Regulation of c-erbA-alpha messenger RNA species in tadpole erythrocytes by thyroid hormone.","date":"1991","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/1645454","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1347913","id":"PMC_1347913","title":"The v-erbA oncogene requires cooperation with tyrosine kinases to arrest erythroid differentiation induced by ligand-activated endogenous c-erbA and retinoic acid receptor.","date":"1992","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1347913","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1656222","id":"PMC_1656222","title":"The thyroid hormone receptor gene (c-erbA alpha) is expressed in advance of thyroid gland maturation during the early embryonic development of Xenopus laevis.","date":"1991","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1656222","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2553781","id":"PMC_2553781","title":"Expression of the ErbA-beta class of thyroid hormone receptors is selectively lost in human colon carcinoma.","date":"1989","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/2553781","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26037512","id":"PMC_26037512","title":"A Novel Mutation in THRA Gene Associated With an Atypical Phenotype of Resistance to Thyroid Hormone.","date":"2015","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26037512","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6087351","id":"PMC_6087351","title":"Cellular homologs of the avian erythroblastosis virus erb-A and erb-B genes are syntenic in mouse but asyntenic in man.","date":"1984","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/6087351","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1672166","id":"PMC_1672166","title":"Ontogeny of the v-erbA oncoprotein from the thyroid hormone receptor: an alteration in the DNA binding domain plays a role crucial for v-erbA function.","date":"1991","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/1672166","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3036525","id":"PMC_3036525","title":"Nucleotide sequence of the chicken proto-oncogene c-erbA corresponding to domain 1 of v-erbA.","date":"1987","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3036525","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2160381","id":"PMC_2160381","title":"Expression of erbA alpha and beta mRNAs in regions of adult rat brain.","date":"1990","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/2160381","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11726557","id":"PMC_11726557","title":"Suppression of the deafness and thyroid dysfunction in Thrb-null mice by an independent mutation in the Thra thyroid hormone receptor alpha gene.","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11726557","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9482666","id":"PMC_9482666","title":"Identification and characterization of a novel corepressor interaction region in RVR and Rev-erbA alpha.","date":"1998","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/9482666","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7904604","id":"PMC_7904604","title":"Roles of v-erbA homodimers and heterodimers in mediating dominant negative activity by v-erbA.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7904604","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8102652","id":"PMC_8102652","title":"NeP1. A ubiquitous transcription factor synergizes with v-ERBA in transcriptional silencing.","date":"1993","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8102652","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2847034","id":"PMC_2847034","title":"Genetic dissection of functional domains within the avian erythroblastosis virus v-erbA oncogene.","date":"1988","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2847034","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10493974","id":"PMC_10493974","title":"The v-erbA oncogene (review).","date":"1999","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10493974","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8061332","id":"PMC_8061332","title":"The erbA/thyroid hormone receptor genes in development of the central nervous system.","date":"1994","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/8061332","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1968105","id":"PMC_1968105","title":"Sequence-specific DNA binding by the v-erbA oncogene protein of avian erythroblastosis virus.","date":"1990","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/1968105","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2460752","id":"PMC_2460752","title":"Triiodothyronine nuclear binding capacity in rat tissues correlates with a 6.0 kilobase (kb) and not a 2.6 kb messenger ribonucleic acid hybridization signal generated by a human c-erbA probe.","date":"1988","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/2460752","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3614196","id":"PMC_3614196","title":"The chicken c-erbA proto-oncogene is preferentially expressed in erythrocytic cells during late stages of differentiation.","date":"1987","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/3614196","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30500912","id":"PMC_30500912","title":"Bisphenol A Alters Bmal1, Per2, and Rev-Erba mRNA and Requires Bmal1 to Increase Neuropeptide Y Expression in Hypothalamic Neurons.","date":"2019","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30500912","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9857194","id":"PMC_9857194","title":"Leukemic transformation by the v-ErbA oncoprotein entails constitutive binding to and repression of an erythroid enhancer in vivo.","date":"1998","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9857194","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1349165","id":"PMC_1349165","title":"V-erbA and c-erbA proteins enhance transcriptional activation by c-jun.","date":"1992","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1349165","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8134111","id":"PMC_8134111","title":"Unliganded c-erbA/thyroid hormone receptor induces trkB expression in neuroblastoma cells.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8134111","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2904357","id":"PMC_2904357","title":"Antipeptide antibodies recognize c-erbA and a related protein in human A431 carcinoma cells.","date":"1988","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/2904357","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1969136","id":"PMC_1969136","title":"Requirement for the C-terminal domain of the v-erbA oncogene protein for biological function and transcriptional repression.","date":"1990","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1969136","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1967151","id":"PMC_1967151","title":"A subpopulation of the avian erythroblastosis virus v-erbA protein, a member of the nuclear hormone receptor family, is glycosylated.","date":"1990","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/1967151","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9264411","id":"PMC_9264411","title":"Mechanism of transformation by v-ErbA: substitution for steroid hormone receptor function in self renewal induction.","date":"1997","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9264411","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2158623","id":"PMC_2158623","title":"The chicken c-erbA alpha-product induces expression of thyroid hormone-responsive genes in 3,5,3'-triiodothyronine receptor-deficient rat hepatoma cells.","date":"1990","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/2158623","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7923937","id":"PMC_7923937","title":"Cloning of a thyroid hormone-responsive Rana catesbeiana c-erbA-beta gene.","date":"1994","source":"Developmental genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7923937","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29205102","id":"PMC_29205102","title":"CRISPR/Cas9 Editing of the Mouse Thra Gene Produces Models with Variable Resistance to Thyroid Hormone.","date":"2018","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/29205102","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8455948","id":"PMC_8455948","title":"Characterization of a functional promoter for the human thyroid hormone receptor alpha (c-erbA-1) gene.","date":"1993","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8455948","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8015547","id":"PMC_8015547","title":"Rat Rev-erbA alpha, an orphan receptor related to thyroid hormone receptor, binds to specific thyroid hormone response elements.","date":"1994","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/8015547","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1347919","id":"PMC_1347919","title":"The nuclear oncogenes v-erbA and v-ets cooperate in the induction of avian erythroleukemia.","date":"1992","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/1347919","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30842990","id":"PMC_30842990","title":"New Case of Thyroid Hormone Resistance α Caused by a Mutation of THRA /TRα1.","date":"2019","source":"Journal of the Endocrine Society","url":"https://pubmed.ncbi.nlm.nih.gov/30842990","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8386604","id":"PMC_8386604","title":"Ontogeny of thyroid hormone receptors and c-erbA expression during brown adipose tissue development: evidence of fetal acquisition of the mature thyroid status.","date":"1993","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/8386604","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7916146","id":"PMC_7916146","title":"c-ErbA, but not v-ErbA, competes with a putative erythroid repressor for binding to the carbonic anhydrase II promoter.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7916146","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15650025","id":"PMC_15650025","title":"Cancer promoted by the oncoprotein v-ErbA may be due to subcellular mislocalization of nuclear receptors.","date":"2005","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15650025","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"390305","id":"PMC_390305","title":"Construction and expression of a hybrid plasmid containing the Escherichia coli thrA and thrB genes.","date":"1979","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/390305","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8102105","id":"PMC_8102105","title":"ErbA: tumor suppressor turned oncogene?","date":"1993","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/8102105","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32204686","id":"PMC_32204686","title":"Two Novel Cases of Resistance to Thyroid Hormone Due to THRA Mutation.","date":"2020","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/32204686","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8616895","id":"PMC_8616895","title":"A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8616895","citation_count":1894,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22658674","id":"PMC_22658674","title":"Insights into RNA biology from an atlas of mammalian mRNA-binding proteins.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22658674","citation_count":1718,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7566114","id":"PMC_7566114","title":"Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7566114","citation_count":1694,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7566127","id":"PMC_7566127","title":"A transcriptional co-repressor that interacts with nuclear hormone receptors.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7566127","citation_count":1679,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2879243","id":"PMC_2879243","title":"The c-erb-A gene encodes a thyroid hormone receptor.","date":"1986","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2879243","citation_count":1504,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2879242","id":"PMC_2879242","title":"The c-erb-A protein is a high-affinity receptor for thyroid hormone.","date":"1986","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/2879242","citation_count":1317,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9267036","id":"PMC_9267036","title":"Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300.","date":"1997","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9267036","citation_count":1255,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19274049","id":"PMC_19274049","title":"A census of human transcription factors: function, expression and evolution.","date":"2009","source":"Nature reviews. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19274049","citation_count":1191,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1310350","id":"PMC_1310350","title":"Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors.","date":"1992","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1310350","citation_count":932,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10235266","id":"PMC_10235266","title":"Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex.","date":"1999","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/10235266","citation_count":583,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20211142","id":"PMC_20211142","title":"An atlas of combinatorial transcriptional regulation in mouse and man.","date":"2010","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/20211142","citation_count":573,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12871948","id":"PMC_12871948","title":"Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12871948","citation_count":554,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8710870","id":"PMC_8710870","title":"Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8710870","citation_count":466,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8650544","id":"PMC_8650544","title":"An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors.","date":"1996","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8650544","citation_count":441,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1314167","id":"PMC_1314167","title":"RXR alpha, a promiscuous partner of retinoic acid and thyroid hormone receptors.","date":"1992","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/1314167","citation_count":433,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7776974","id":"PMC_7776974","title":"Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor.","date":"1995","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/7776974","citation_count":408,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9653119","id":"PMC_9653119","title":"The TRAP220 component of a thyroid hormone receptor- associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9653119","citation_count":381,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10198638","id":"PMC_10198638","title":"Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators.","date":"1999","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10198638","citation_count":353,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16799563","id":"PMC_16799563","title":"An ARC/Mediator subunit required for SREBP control of cholesterol and lipid homeostasis.","date":"2006","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16799563","citation_count":335,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28611215","id":"PMC_28611215","title":"Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28611215","citation_count":282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3672126","id":"PMC_3672126","title":"A novel thyroid hormone receptor encoded by a cDNA clone from a human testis library.","date":"1987","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/3672126","citation_count":237,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9628876","id":"PMC_9628876","title":"Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators.","date":"1998","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9628876","citation_count":218,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19158403","id":"PMC_19158403","title":"L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase.","date":"2009","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19158403","citation_count":208,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21988832","id":"PMC_21988832","title":"Toward an understanding of the protein interaction network of the human liver.","date":"2011","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/21988832","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43344,"output_tokens":7386,"usd":0.120411},"stage2":{"model":"claude-opus-4-6","input_tokens":11204,"output_tokens":3775,"usd":0.225593},"total_usd":0.771725,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":54834,"output_tokens":14122,"usd":0.188166},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":17244,"output_tokens":2886,"usd":0.237555}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"The v-erbA protein (oncogenic derivative of the thyroid hormone receptor/THRA) acts as a constitutive repressor of thyroid hormone-responsive promoters and, when coexpressed with c-erbA/THRA, blocks transcriptional activation by thyroid hormone, establishing v-erbA as a dominant negative oncogene.\",\n      \"method\": \"Transient transfection reporter assays, co-expression experiments in cell lines\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal functional assays, replicated across labs and foundational citation with 616 citations\",\n      \"pmids\": [\"2733791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Alternative splicing of the c-erbA alpha (THRA) gene transcript generates r-erbA alpha-2, a protein that binds the same DNA sequences as the thyroid hormone receptor but does not bind T3; r-erbA alpha-2 inhibits T3-dependent transcriptional induction by functional T3 receptors, establishing a mechanism of endogenous hormonal antagonism.\",\n      \"method\": \"cDNA cloning, in vitro translation, T3 binding assay, transient transfection reporter assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding assay combined with functional reporter assay; replicated by multiple labs (PMIDs 2903438, 2554288)\",\n      \"pmids\": [\"2537467\", \"2903438\", \"2554288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The c-erbA alpha-encoded thyroid hormone receptor (TRα1/THRA) is phosphorylated on serine residues at two distinct sites in its amino-terminal domain; phosphorylation at Ser28/Ser29 is enhanced by activation of either protein kinase C or cAMP-dependent protein kinase, and cAMP-dependent protein kinase directly phosphorylates c-erbA alpha in vitro at this site.\",\n      \"method\": \"Metabolic labeling, tryptic phosphopeptide mapping, in vitro kinase assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay combined with in vivo phosphopeptide mapping\",\n      \"pmids\": [\"2903825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"The hormone-binding domain of the chicken c-erbA/TRα (THRA) resides in the carboxy-terminal half of the protein, analogous to steroid receptors; multiple mutations in the carboxy-terminal half of v-erbA cooperate to abolish hormone binding, and a point mutation between the DNA- and ligand-binding domains that inactivates v-erbA biologically does not affect hormone binding, implicating this region in transcriptional regulation rather than ligand binding.\",\n      \"method\": \"Chimeric c-erbA/v-erbA protein analysis, ligand binding assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-function chimeric mutagenesis with biochemical binding validation\",\n      \"pmids\": [\"3359993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Casein kinase II phosphorylates c-erbA alpha (THRA) at serine 12 in its amino-terminal domain; this site is within a canonical casein kinase II consensus motif, is phosphorylated in vitro by purified casein kinase II at the same site as observed in vivo, and alanine substitution at Ser12 abolishes phosphorylation by casein kinase II in vitro.\",\n      \"method\": \"In vitro kinase assay with purified casein kinase II, 2D phosphopeptide mapping, site-directed mutagenesis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis and 2D phosphopeptide mapping\",\n      \"pmids\": [\"2552374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Phosphorylation of Ser-16/17 in the v-erbA (THRA-derived oncoprotein) is required for its full biological activity (inhibition of erythroid differentiation and repression of erythrocyte-specific genes band 3 and carbonic anhydrase II); alanine substitution at these serines abolishes phosphorylation and biological activity without affecting nuclear localization or DNA binding, while the protein kinase inhibitor H7 inhibits v-erbA phosphorylation and induces differentiation.\",\n      \"method\": \"Site-directed mutagenesis, back-mutation analysis, in vivo differentiation assay, pharmacological inhibition\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mutagenesis with multiple functional readouts and pharmacological validation\",\n      \"pmids\": [\"1979040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The v-erbA oncoprotein has lost hormone-dependent transcriptional regulatory activity of c-erbA/TRα (THRA); chimeric analysis maps the loss of hormone-dependent regulator activity to the very C-terminus of c-erbA, a cluster of conserved amino acids with potential to form an amphipathic alpha-helix, while retaining constitutive repressor activity.\",\n      \"method\": \"Chimeric v-/c-erbA protein expression in erythroid cells, transcription assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — chimeric protein domain mapping with functional erythroid differentiation and transcription readouts\",\n      \"pmids\": [\"1972036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The v-erbA oncogene specifically suppresses transcription of the erythrocyte anion transporter (band 3) gene at the transcriptional level in differentiating erythroblasts; this transcriptional suppression is reversible and correlates with the v-erbA-induced differentiation block.\",\n      \"method\": \"Transcription assays, pH-manipulation to alter v-erbA activity, gene expression analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — defined transcriptional target with functional phenotypic correlation and reversibility controls\",\n      \"pmids\": [\"2830979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"v-erbA and c-erbA (THRA) bind directly to sequences within the carbonic anhydrase II (CAII) promoter; this binding site confers thyroid hormone responsiveness in transient expression experiments; c-erbA activity is dominant over v-erbA at equimolar concentrations, requiring v-erbA overexpression to suppress c-erbA-mediated activation.\",\n      \"method\": \"Direct DNA binding (EMSA/footprinting), transient transfection reporter assays, stable co-expression studies\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct DNA binding combined with transient and stable expression functional assays\",\n      \"pmids\": [\"1682217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Ligand-activated c-ErbA alpha (THRA) and RAR alpha repress AP-1-mediated transcriptional activation of the interstitial collagenase gene promoter by decreasing AP-1 activity; v-ErbA fails to repress AP-1 and acts as a dominant negative by overcoming RAR alpha/c-ErbA alpha-mediated AP-1 repression.\",\n      \"method\": \"Transient transfection reporter assays with AP-1-responsive promoter\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter assays establishing mechanism of AP-1 cross-repression\",\n      \"pmids\": [\"1682056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"A conserved 9-amino acid C-terminal region of c-ErbA alpha (THRA), deleted in v-ErbA, is essential for T3-dependent transcriptional activation, interference with AP-1 activity, and induction of erythroid differentiation; single, double, and triple amino acid substitutions within this region abolish all these activities, and deletion of homologous residues in RAR alpha causes the same loss of function.\",\n      \"method\": \"c-ErbA/v-ErbA chimeras, site-directed mutagenesis, transient transfection assays, erythroid differentiation assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal assays with systematic mutagenesis across two receptor family members\",\n      \"pmids\": [\"8098843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"A novel hormone-responsive element (RSV-T3RE) mediates strong ligand-independent activation by c-ErbA alpha (THRA) through its unique N-terminal activation domain, while classical T3RE-mediated activation requires the C-terminal activation domain; c-ErbA alpha assumes a different conformation when bound to RSV-T3RE versus classical T3RE, enabling selective deployment of activation domains.\",\n      \"method\": \"Transient transfection reporter assays, domain deletion analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain mapping with multiple response elements showing distinct activation domain requirements\",\n      \"pmids\": [\"7903219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Unliganded c-ErbA/TRα (THRA) in the absence of T3 inhibits NGF-induced neuronal differentiation and represses neuron-specific gene expression in PC12 cells, while in the presence of T3, it permits normal differentiation; the receptor also constitutively blocks dexamethasone-induced chromaffin differentiation, demonstrating a role for TRα1 in regulating commitment and maturation of neuronal progenitors.\",\n      \"method\": \"Stable expression of chicken c-erbA/TRα1 in PC12 cells, differentiation assays, gene expression analysis\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss/gain-of-function with defined cellular phenotype and multiple differentiation pathway readouts\",\n      \"pmids\": [\"8385673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Unliganded TRα (THRA), but not v-ErbA, suppresses RAR-dependent transactivation by competing for the common dimerization partner RXR; co-transfection of RXR alleviates TRα-mediated suppression; TRα, but not v-ErbA, competes with RAR for RXR and causes dissociation of a preformed RAR/RXR-RARE ternary complex in vitro; a single point mutation in v-erbA's dimerization interface abolishes this effect when introduced into TRα.\",\n      \"method\": \"Co-transfection assays, in vitro competition EMSA, site-directed mutagenesis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of RXR competition combined with mutagenesis and cell-based assays\",\n      \"pmids\": [\"8096810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"v-erbA oncoprotein can substitute for ligand-activated glucocorticoid receptor (GR) and estrogen receptor (ER) in inducing proliferation and arresting differentiation of erythroid progenitors; this activity requires cooperation with c-Kit receptor tyrosine kinase and depends on distinct mutations in v-ErbA's DNA-binding domain.\",\n      \"method\": \"Retroviral expression, receptor antagonist experiments, erythroid differentiation/proliferation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assays with pharmacological antagonists and DNA-binding domain mutagenesis, single lab\",\n      \"pmids\": [\"9264411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"A missense difference in the zinc finger DNA-binding domain between v-erbA and c-erbA (THRA) has dramatic effects on biological activities; back-mutation of the viral coding sequence at this position severely impairs erythroid transformation and produces subtle changes in DNA binding, implicating differences in DNA binding in oncogenic activation of v-erbA.\",\n      \"method\": \"Site-directed back-mutagenesis, erythroid transformation assays, DNA binding analysis\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis with biological and biochemical readouts, single lab\",\n      \"pmids\": [\"1672166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Rev-ErbA alpha mRNA (encoded on the opposite strand of the c-erbA alpha/THRA locus) inhibits splicing of c-erbA alpha-2 pre-mRNA in vitro through antisense base pairing, thereby potentially regulating the ratio of alpha-1 (T3 receptor) to alpha-2 (non-T3-binding inhibitor) splice products.\",\n      \"method\": \"In vitro splicing assay with antisense RNA addition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of splicing inhibition with complementary RNA specificity controls\",\n      \"pmids\": [\"1657988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"v-ErbA and TRα (THRA) recruit the corepressor N-CoR concomitantly with HDAC3 (but not Sin3, HDAC1/RPD3, Mi-2, or HDAC5) to repress transcription; v-ErbA requires fully mature chromatin for repression whereas TRα does not, and v-ErbA is less competent than TRα for binding to TFIIB both in vitro and in vivo.\",\n      \"method\": \"Xenopus oocyte chromatin assembly, HDAC inhibitor treatment, coimmunoprecipitation, in vitro TFIIB binding assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution in Xenopus oocytes with multiple orthogonal methods including in vitro binding and chromatin-specific assays\",\n      \"pmids\": [\"10921888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Rev-erbA alpha and RVR (orphan receptors encoded from the THRA locus antisense strand) interact with corepressor N-CoR/RIP13 through two receptor interaction domains (ID-I and ID-II) that together are required for efficient interaction; this interaction is dependent on an intact E region (ligand-binding domain) of Rev-erbA alpha/RVR, and dominant-negative N-CoR interaction domains alleviate orphan receptor-mediated repression.\",\n      \"method\": \"Mammalian two-hybrid assay, co-transfection with dominant-negative corepressor fragments, deletion analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — two-hybrid and transfection assays, single lab\",\n      \"pmids\": [\"8948627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The Rev-erbA/RVR ligand-binding domain presents a large hydrophobic surface (H3, loop 3-4, H4, H11) due to absence of the C-terminal activation helix H12; mutation of specific residues on this surface severely impairs interaction with N-CoR/RIP13delta1 in vitro and in vivo, and reduces repressor activity; the putative ligand cavity is occupied by side chains, suggesting absence of endogenous ligands.\",\n      \"method\": \"Homology modeling, site-directed mutagenesis, in vitro and in vivo protein interaction assays, cotransfection reporter assays\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — structural modeling validated by mutagenesis and functional assays with multiple orthogonal methods\",\n      \"pmids\": [\"10809233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"v-ErbA is constitutively bound to a response element (VRE) within an intronic DNase I hypersensitive site of the CAII gene in transformed erythroblasts in vivo; mutation of the VRE converts the repressed region into a potent enhancer; differentiation alleviates v-ErbA binding concomitant with CAII activation; histone deacetylase inhibitor trichostatin A derepresses the endogenous chromatin-embedded CAII gene.\",\n      \"method\": \"In vivo footprinting, transfection with VRE mutants, HDAC inhibitor treatment, ligand-induced derepression assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo footprinting demonstrating constitutive chromatin occupancy, validated by mutagenesis and pharmacological approaches\",\n      \"pmids\": [\"9857194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"v-ErbA dimerizes with TRα (THRA) and RXR and sequesters a significant fraction of both nuclear receptors in the cytoplasm; cytoplasmic recruitment of TRα by v-ErbA can be partially reversed by T3 ligand or by histone deacetylase inhibitor trichostatin A, defining cytoplasmic sequestration as an additional mechanism of v-ErbA dominant-negative activity.\",\n      \"method\": \"Co-immunoprecipitation, subcellular localization assays, pharmacological reversal experiments\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP and localization with pharmacological validation, single lab\",\n      \"pmids\": [\"15650025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A targeted mutation (Thra tm2) in the mouse Thra gene that deletes TR alpha 2 and causes overexpression of TR alpha 1 suppresses the deafness and thyroid hyperactivity caused by Thrb deletion; TR alpha 2 is dispensable for hearing, and increased TR alpha 1 expression can substitute for absent TR beta, establishing TRα1 as capable of compensating for TRβ functions.\",\n      \"method\": \"Genetic epistasis via double-mutant mice (Thra tm2 x Thrb null), auditory threshold testing, thyroid function assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic epistasis in vivo with defined physiological phenotype\",\n      \"pmids\": [\"11726557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Truncating and missense mutations in THRA cause resistance to thyroid hormone α (RTHα) with a consistent phenotype (hypothyroid-like features, altered T4:T3 ratio, normal TSH); missense mutations cause milder outcomes than truncating mutations, indicating genotype-phenotype correlation dependent on mutant TRα1 function.\",\n      \"method\": \"Whole exome sequencing, Sanger sequencing, clinical and biochemical characterization\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — genetic/clinical characterization without direct in vitro mechanistic assay in this paper\",\n      \"pmids\": [\"25670821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A de novo THRA missense mutation (N359Y) produces a mutant TRα1 with decreased T3 binding affinity, reduced transcriptional activity, and dominant-negative effect on wild-type receptor, causing severe RTHα with bone malformations, dwarfism, and altered metabolism.\",\n      \"method\": \"Whole exome sequencing, transcriptional activity assays, T3 binding assay, dominant-negative testing\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct biochemical assays (T3 binding, transcriptional activity, dominant-negative) validating the pathogenic mechanism\",\n      \"pmids\": [\"26037512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CRISPR/Cas9-generated missense and frameshift mutations in mouse Thra recapitulate RTHα phenotype with severity correlating with the mutant TRα1's ability to interact with transcriptional corepressor in the presence of thyroid hormone.\",\n      \"method\": \"CRISPR/Cas9 genome editing, phenotypic characterization, corepressor interaction assays\",\n      \"journal\": \"Thyroid\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo genetic model combined with biochemical corepressor interaction assays\",\n      \"pmids\": [\"29205102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Novel THRA missense mutations (M259T, T273A) in RTHα patients reduce TRα1 affinity for T3 and prevent corepressor dissociation from mutant TRα1 in the presence of T3, establishing that the severity of RTHα correlates with the inability of the mutant receptor to release corepressors upon T3 binding.\",\n      \"method\": \"Biochemical T3 binding assays, corepressor interaction assays, in silico structural modeling, transcriptional reporter assays\",\n      \"journal\": \"Thyroid\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal biochemical assays (ligand binding, corepressor interaction, transcriptional activity)\",\n      \"pmids\": [\"32204686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The c-erbA proto-oncogene (THRA) encodes a nuclear receptor that, when expressed in T3 receptor-deficient rat hepatoma cells (FAO), confers thyroid hormone responsiveness to multiple endogenous T3-responsive genes (malic enzyme, phosphoenolpyruvate carboxykinase, Na+/K+-ATPase) and directly activates a reporter promoter in a ligand-dependent manner.\",\n      \"method\": \"Retroviral expression of cTR-alpha in receptor-deficient FAO cells, endogenous gene expression analysis, reporter assays\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor-deficient reconstitution system with multiple endogenous gene readouts\",\n      \"pmids\": [\"2158623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"Unliganded c-erbA alpha (THRA) expressed in neuroblastoma (N2a) cells induces trkB mRNA expression and simultaneously suppresses trkA and trkC mRNAs in a ligand-independent manner; the induced trkB encodes a functional gp145trkB protein that is phosphorylated on tyrosine in response to BDNF.\",\n      \"method\": \"Stable transfection, Northern blotting, tyrosine phosphorylation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — defined transcriptional target with functional receptor validation, single lab\",\n      \"pmids\": [\"8134111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"The genomic organization of human THRA (c-erbA-1) consists of 10 exons over 27 kb on chromosome 17; each zinc finger of the DNA-binding domain is encoded by a separate exon; the hormone-binding domain is assembled from three exons; the two last exons are alternatively spliced to generate different mRNAs; the ear-1 (Rev-ErbA) gene overlaps the 3' region of THRA in opposite transcriptional orientation.\",\n      \"method\": \"Genomic cloning, restriction mapping, DNA sequencing, exon-intron boundary analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct genomic sequencing and structural characterization\",\n      \"pmids\": [\"1850510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"v-erbA forms homodimers and heterodimers (with RXR, T3 receptor auxiliary protein, and TRα) that bind to thyroid hormone response elements (TREs); T3 at high concentration decreases v-erbA homodimer binding; v-erbA cannot mediate ligand-dependent transcriptional activation even at high T3 but blocks TR-mediated transactivation; v-ErbA shows differential dominant-negative activity on different TRE configurations.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA), co-transfection reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vitro DNA binding and cell-based assays, single lab\",\n      \"pmids\": [\"7904604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The v-erbA oncoprotein acts as a hormone-regulated transcriptional activator in S. cerevisiae, in contrast to its constitutive repressor function in animal cells, indicating that the repressor versus activator activity is determined by interaction with or modification by other cellular factors.\",\n      \"method\": \"Yeast transcriptional activation assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assay in heterologous system revealing context-dependence of repressor/activator switch\",\n      \"pmids\": [\"1979758\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"THRA encodes thyroid hormone receptor alpha-1 (TRα1), a ligand-dependent nuclear transcription factor that, when unliganded, recruits corepressors (N-CoR/HDAC3) to repress target gene transcription, and upon T3 binding releases corepressors and activates transcription through C-terminal activation domains; alternative splicing generates TRα2 (which binds DNA but not T3 and inhibits TRα1 activity), while the opposite genomic strand encodes Rev-ErbA alpha (an orphan repressor that also regulates TRα2 splicing via antisense RNA); TRα1 is phosphorylated by casein kinase II (Ser12) and PKA/PKC (Ser28/29), modifications required for full transcriptional and oncogenic activity; loss-of-function mutations in THRA cause resistance to thyroid hormone alpha (RTHα) by reducing T3 binding affinity and preventing corepressor release, with phenotype severity correlating with the degree of corepressor retention in the presence of T3.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll systematically classify each paper before extracting discoveries.\n\n**CLASSIFICATION:**\n\n**KEEP (canonical THRA/TRα protein):**\n- Papers 2, 3, 5, 6, 7, 9, 10, 11, 12, 13, 21, 22, 23, 24, 25, 26, 28, 29, 31, 32, 33, 34, 36, 38, 39, 40, 41, 42, 43, 44, 45, 47, 51, 52, 53, 54, 56, 57, 58, 59, 61, 62, 63, 65, 67, 68, 70, 72, 73, 74, 75, 77, 79, 81, 82, 83, 85, 86, 87, 88, 90, 91, 94, 96, 97, 99, 100\n- Curated: 3, 4, 5, 7, 8, 12, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 27, 28, 29\n\n**EXCLUDE:**\n- Paper 1: Chicken estrogen receptor (ER), not THRA\n- Paper 4: c-erbB-2/c-erbA amplification — epidemiological/genomic, no mechanistic THRA finding\n- Paper 8: c-erbB-2/c-erbA amplification in stomach cancer — genomic association only\n- Paper 14: c-erbA beta (THRB) mutations — THRB not THRA\n- Paper 15: ear-2, ear-3 genes — not THRA\n- Paper 16: Rev-ErbA alpha (NR1D1) — different gene on opposite strand\n- Paper 17: chromosomal localization only\n- Paper 18: expression pattern only\n- Paper 19: c-erbA beta (THRB) — not THRA\n- Paper 20: THRB linkage — not THRA\n- Paper 27: chromosomal localization\n- Paper 30: c-erbA beta/c-erbA2 in breast cancer — genomic\n- Paper 37: expression analysis\n- Paper 46: E. coli thrA gene — SYMBOL COLLISION (bacterial gene)\n- Paper 48: c-erbB-2/c-erbA co-amplification — epidemiological\n- Paper 49: Rev-ErbA alpha/RVR corepressor — NR1D1\n- Paper 50: v-erbA in Xenopus — KEEP (functional test of THRA/v-erbA)\n- Paper 55: THRB mutation — not THRA\n- Paper 60: Rev-ErbA/RVR structure — NR1D1\n- Paper 64: expression analysis\n- Paper 66: chromosomal localization\n- Paper 69: expression pattern only\n- Paper 71: Rev-ErbA alpha/RVR — NR1D1\n- Paper 76: review/no mechanistic data\n- Paper 78: expression correlation only\n- Paper 80: Rev-Erbα circadian — NR1D1 context, BPA study\n- Paper 84: antipeptide antibody — hc-erbA-beta (THRB)\n- Paper 89: Rana TR beta — THRB\n- Paper 92: Rev-erbA alpha — NR1D1\n- Paper 93: v-erbA + v-ets cooperation — KEEP (v-erbA/THRA mechanism)\n- Paper 95: expression pattern\n- Paper 98: E. coli thrA/thrB — SYMBOL COLLISION\n- Curated 1: CBP — general nuclear receptor, mentions TR but not THRA-specific mechanism → borderline KEEP (directly tested with TRα)\n- Curated 2: mRNA-binding proteins — no THRA mechanism\n- Curated 3: N-CoR/ligand-independent repression — directly about TR (THRA) → KEEP\n- Curated 4: SMRT corepressor — directly about TR → KEEP\n- Curated 5: c-erb-A encodes thyroid hormone receptor → KEEP (foundational)\n- Curated 6: MGC cDNA library — no mechanism\n- Curated 7: c-erb-A is high-affinity thyroid hormone receptor → KEEP\n- Curated 8: ACTR/histone acetyltransferase — nuclear receptor coactivator, mentions TR → KEEP\n- Curated 9: transcription factor census — no mechanism\n- Curated 10: BioPlex interactome — no THRA-specific mechanism\n- Curated 11: proteome interactome — no mechanism\n- Curated 12: RXR alpha auxiliary protein for TR → KEEP\n- Curated 13: HuRI interactome — no mechanism\n- Curated 14: GO phylogenetic — no mechanism\n- Curated 15: DRIP complex/ligand-dependent transactivation by TR → KEEP\n- Curated 16: TF combinatorial atlas — no THRA mechanism\n- Curated 17: MCT8 thyroid hormone transporter — not THRA protein mechanism\n- Curated 18: TRAP complex/TR coactivator → KEEP\n- Curated 19: SHP orphan receptor interacts with TR → KEEP\n- Curated 20: MGC — no mechanism\n- Curated 21: RXR alpha dimerization partner for TR → KEEP\n- Curated 22: TRIP proteins interacting with TR → KEEP\n- Curated 23: TRAP220 interacts with TRα → KEEP\n- Curated 24: TRAP/SMCC identity → KEEP\n- Curated 25: ARC/Mediator — mentions nuclear receptors broadly, not THRA-specific\n- Curated 26: HNRNPL/prostate cancer — no THRA mechanism\n- Curated 27: novel thyroid hormone receptor (erbA-T/TRα) → KEEP\n- Curated 28: NSD1 interacts with TR → KEEP\n- Curated 29: T3/T4 cell proliferation, TRα trafficking → KEEP\n- Curated 30: human liver interaction network — no THRA-specific mechanism\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1986,\n      \"finding\": \"The c-erb-A protein was identified as a high-affinity receptor for thyroid hormone (T3/T4). The protein is nuclear-localized and binds to DNA, while the viral oncogene product v-erb-A is defective in hormone binding but retains nuclear localization.\",\n      \"method\": \"Hormone binding assays, nuclear localization studies, comparison of c-erbA and v-erbA proteins\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — foundational ligand-binding demonstration, replicated independently in two simultaneous papers (PMIDs 2879242 and 2879243)\",\n      \"pmids\": [\"2879242\", \"2879243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"A novel thyroid hormone receptor (erbA-T/TRα) encoded by a human testis cDNA clone was shown to bind T3 with high affinity (Kd ~0.38 nM), establishing that multiple human thyroid hormone receptor isoforms exist with potentially different tissue specificities.\",\n      \"method\": \"cDNA cloning, in vitro binding assay (T3 binding with Scatchard analysis)\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding assay with quantitative Kd measurement\",\n      \"pmids\": [\"3672126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The c-erbA alpha-encoded thyroid hormone receptor (TRα) is phosphorylated on serine residues at two distinct sites in its amino-terminal domain. Activation of either protein kinase C (PKC) or cAMP-dependent protein kinase (PKA) enhances phosphorylation at one shared site (Ser28/29), and PKA phosphorylates this site directly in vitro, identifying PKA as a writer of TRα phosphorylation.\",\n      \"method\": \"In vivo phosphorylation labeling, tryptic phosphopeptide mapping, in vitro kinase assay with purified PKA\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay with peptide mapping confirming same site as in vivo phosphorylation\",\n      \"pmids\": [\"2903825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Alternative splicing of the rat c-erbA alpha (Thra) primary transcript generates r-erbA alpha-2, a protein that retains the DNA-binding domain but lacks T3-binding capacity, and which inhibits T3-dependent transcriptional activation by functional T3 receptors (r-erbA alpha-1 and r-erbA beta).\",\n      \"method\": \"cDNA cloning, in vitro T3 binding assay, transient transfection reporter assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted T3 binding failure confirmed in vitro; functional inhibition shown in cell-based reporter assay; replicated across species\",\n      \"pmids\": [\"2537467\", \"2903438\", \"2554288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The hormone-binding domain of chicken c-erbA (TRα) resides in the carboxy-terminal half of the protein. Multiple mutations present in the carboxy-terminal half of v-erbA cooperate to abolish hormone binding, and a point mutation between the DNA- and ligand-binding domains that abolishes v-erbA biological activity does not affect hormone binding, indicating this region controls transcriptional activity independently of hormone binding.\",\n      \"method\": \"Chimeric c-erbA/v-erbA protein analysis, in vitro T3 binding assay, site-directed mutagenesis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with chimeric proteins and mutagenesis pinpointing functional domains\",\n      \"pmids\": [\"3359993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"Both c-erbA-alpha (chicken) and c-erbA-beta (human placenta) can function as hormone-dependent modulators of thyroid-hormone-responsive genes (rat GH and PRL). In receptor-deficient cells both act as classical T3 receptors, while in receptor-containing cells they modulate transcription in a hormone-independent manner, demonstrating that events other than ligand binding can activate TRα.\",\n      \"method\": \"Transient transfection reporter assays in multiple cell lines (receptor-deficient and receptor-containing)\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean cell-based functional assay with defined receptor-null vs. receptor-containing contexts; single lab\",\n      \"pmids\": [\"2903439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"The v-erbA oncogene protein acts as a constitutive transcriptional repressor and dominant negative antagonist of the thyroid hormone receptor (TRα/c-erbA): when coexpressed with TRα, v-erbA blocks thyroid hormone-induced gene activation. Unliganded TRα itself suppresses responsive promoter activity, but hormone converts it to an activator.\",\n      \"method\": \"Transient co-transfection reporter assays; dominant negative functional analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean co-transfection epistasis with defined receptor; replicated across multiple labs\",\n      \"pmids\": [\"2733791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"The c-erbA alpha (THRA) gene locus on chromosome 17 encodes both TRα1 and TRα2 (via alternative splicing) and overlaps with the Rev-ErbA alpha gene, which is encoded on the opposite DNA strand. A 269-bp segment is exonic in both Rev-ErbA alpha and r-erbA alpha-2 mRNAs, generating complementary RNAs from the same genomic locus.\",\n      \"method\": \"Genomic DNA isolation and sequencing, cDNA cloning, Northern blotting, exon mapping\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct genomic sequencing and structural characterization; independently corroborated by multiple labs\",\n      \"pmids\": [\"2542765\", \"2539258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"c-ErbA alpha (TRα) represses AP-1-mediated transcriptional activation of the interstitial collagenase gene promoter by decreasing AP-1 transcription factor activity in a ligand-activated manner. v-ErbA fails to repress AP-1 and instead acts as a dominant negative by overcoming this repression, maintaining a fully active AP-1 complex.\",\n      \"method\": \"Transient transfection reporter assays, AP-1 activity assays, dominant negative analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean cell-based mechanistic dissection of TRα/AP-1 interaction with defined loss-of-function (v-erbA)\",\n      \"pmids\": [\"1682056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"c-erbA alpha (TRα) phosphorylated on serine 12 by casein kinase II (CK2) in vitro at a site matching the consensus CK2 substrate motif with flanking acidic residues. Site-directed mutagenesis (Ser12→Ala) abolished CK2 phosphorylation in vitro, identifying CK2 as the kinase for this N-terminal site. The CK2-phosphorylated serine 12 is conserved across all T3-binding c-erbA alpha family members but absent in v-erbA.\",\n      \"method\": \"In vitro kinase assay with purified CK2, two-dimensional phosphopeptide mapping, site-directed mutagenesis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with purified kinase plus mutagenesis confirming site identity\",\n      \"pmids\": [\"2552374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"v-erbA oncoprotein requires phosphorylation at Ser-16/17 (in its v-erbA-encoded domain, corresponding to the PKA/PKC phosphorylation site of c-erbA) for its oncogenic function. Ser→Ala substitution abolished phosphorylation and eliminated the ability to block erythroid differentiation and repress erythrocyte-specific genes (band 3, carbonic anhydrase II), while Ser→Thr preserved basal but not PKA/PKC-enhanced phosphorylation and yielded partial activity. H7 kinase inhibitor recapitulated the differentiation-induction phenotype.\",\n      \"method\": \"Site-directed mutagenesis, in vivo phosphorylation assay, biological differentiation assay in transformed erythroblasts, protein kinase inhibitor treatment\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with multiple substitutions, orthogonal pharmacological validation, and defined phenotypic readout\",\n      \"pmids\": [\"1979040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Overexpressed c-erbA (TRα) modulates erythroid differentiation and erythrocyte-specific gene expression in a T3-dependent fashion in erythroid cells. The v-erbA oncoprotein has lost this hormone-dependent regulatory function. Chimeric v-/c-erbA analysis mapped the loss-of-function to the very C-terminus of c-erbA, encompassing a cluster of conserved amino acids with the potential to form an amphipathic alpha-helix.\",\n      \"method\": \"Retroviral expression, chimeric protein analysis, erythroid differentiation assays, gene expression analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic chimera mapping with defined phenotypic readout in physiologically relevant cell system\",\n      \"pmids\": [\"1972036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The v-erbA protein specifically suppresses transcription of the avian erythrocyte anion transporter (band 3) gene at the transcriptional level, establishing band 3 as a direct transcriptional target of v-erbA/TRα. This repression correlates with, and contributes to, the differentiation block caused by v-erbA.\",\n      \"method\": \"Retroviral expression, transcription assays, alkaline pH rescue experiment, pharmacological inhibition of band 3\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with multiple interventions (pH manipulation, inhibitor) and defined transcriptional readout\",\n      \"pmids\": [\"2830979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"In S. cerevisiae, the v-erbA protein unexpectedly acts as a hormone-regulated transcriptional activator rather than a repressor, demonstrating that the repressor activity of v-erbA in animal cells requires interaction with, or modification by, specific cellular factors absent in yeast. This establishes that TRα/v-erbA transcriptional activity is determined by cellular context.\",\n      \"method\": \"Yeast transcriptional activation assay, hormone treatment, cross-species comparison\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean yeast system revealing context-dependence; single lab, single method\",\n      \"pmids\": [\"1979758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"The human THRA gene (c-erbA-1) is organized in 10 exons spanning ~27 kb on chromosome 17. Each zinc finger of the DNA-binding domain is encoded by a separate exon; the hormone-binding domain is assembled from three exons. The last two exons are alternatively spliced to generate TRα1 and TRα2 mRNAs. The genomic locus also encodes the oppositely transcribed ear-1/Rev-ErbA.\",\n      \"method\": \"Genomic DNA cloning, restriction mapping, exon sequencing, comparison with chicken gene\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct genomic structural determination by sequencing\",\n      \"pmids\": [\"1850510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"A 269-bp complementary RNA (antisense to c-erbA alpha-2 mRNA), representing the 3' end of Rev-ErbA alpha mRNA, inhibits splicing of alpha-2 pre-mRNA in vitro, demonstrating that antisense RNA base-pairing can regulate alternative splicing of the Thra locus to favor formation of alpha-1 (TRα1) over alpha-2 mRNA.\",\n      \"method\": \"In vitro splicing assay with added antisense RNA, competition with sense/antisense controls\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro splicing with mechanistic dissection using complementary/non-complementary RNAs\",\n      \"pmids\": [\"1657988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"v-erbA overexpression is required to extinguish c-erbA (TRα) function in erythroid cells. When v-erbA and c-erbA are coexpressed at approximately equimolar levels, c-erbA activity is dominant: T3 induces erythroid differentiation and activates CAII transcription via a direct erbA-binding site in the CAII promoter. Very high v-erbA concentrations are required to suppress c-erbA-dependent activation.\",\n      \"method\": \"Stable co-expression in erythroblasts, T3 treatment, reporter gene assays with CAII erbA-binding site, differentiation assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — quantitative competition analysis in stably transformed cells with defined promoter element\",\n      \"pmids\": [\"1682217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"A single point mutation in the DNA-binding zinc finger domain differentiates v-erbA from c-erbA (TRα): back-mutation of this viral residue to the c-erbA sequence severely impairs erythroid transformation and produces subtle changes in DNA binding, indicating that altered DNA-binding specificity contributes to v-erbA oncogenic activation.\",\n      \"method\": \"Site-directed mutagenesis (back-mutation), erythroid transformation assay, EMSA/DNA binding assay\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis with functional phenotypic readout; single lab\",\n      \"pmids\": [\"1672166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"c-erbA alpha (TRα) and retinoic acid receptor alpha (RARα) cooperate in modulating normal erythroid differentiation. T3 and retinoic acid act synergistically, and the receptor dimerization domain of TRα is required for this functional cooperation, suggesting TRα/RARα heterodimers regulate erythroid differentiation.\",\n      \"method\": \"Primary erythroid progenitor culture, ligand treatment, retroviral receptor overexpression, genetic analysis with dimerization-domain mutants\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with dimerization-domain mutant implicating heterodimerization; single lab\",\n      \"pmids\": [\"1347914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Retinoid X receptor alpha (RXRα) is a required dimerization partner for thyroid hormone receptor (TRα) for stable DNA binding. RXRα co-purifies with TRα, forms heterodimers in solution, and greatly enhances TRα transcriptional activity. TRα is a monomer in solution and cannot form stable homodimeric complexes on response elements without RXRα.\",\n      \"method\": \"Biochemical co-purification, solution binding assays, EMSA, co-transfection reporter assays\",\n      \"journal\": \"Nature / The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution with co-purification and EMSA; replicated independently (PMIDs 1310350, 1314167)\",\n      \"pmids\": [\"1310350\", \"1314167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"A conserved 9-amino acid sequence at the extreme carboxy terminus of c-ErbA alpha (TRα), which is deleted in v-ErbA, is essential for T3-dependent transcriptional activation, AP-1 interference, and induction of erythroid differentiation. Single, double, and triple amino acid substitutions within this region abolish all these activities and reduce T3 binding, but a chimera with similarly reduced T3 binding retains function, showing the C-terminal domain has a role beyond just hormone binding.\",\n      \"method\": \"c-ErbA/v-ErbA chimera analysis, site-directed mutagenesis, reporter assays, differentiation assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with multiple mutants and multiple orthogonal functional readouts\",\n      \"pmids\": [\"8098843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"c-ErbA alpha (TRα) can act as a ligand-independent transcriptional activator through a novel RSV-T3RE response element, distinct from classical T3REs. This activation utilizes a unique N-terminal activation domain and involves either TRα homodimers or TRα/RXR heterodimers. Ligand (T3) reverses activation through this element. DNA binding to the RSV-T3RE induces a different TRα conformation than binding to classical T3REs, demonstrating response-element-directed selective deployment of activation domains.\",\n      \"method\": \"Transient transfection reporter assays, RXR co-transfection, deletion mutagenesis of activation domains\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic domain dissection with multiple deletion mutants, defined response elements, and heterodimerization analysis\",\n      \"pmids\": [\"7903219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"c-erbA alpha (TRα) and v-erbA both enhance c-Jun transcriptional activation in certain promoter contexts, acting as co-activators of AP-1. This reveals a positive transcriptional function for TRα/v-erbA through cooperative interaction with c-Jun, distinct from their repressor activities.\",\n      \"method\": \"Transient co-transfection reporter assays with c-Jun, c-Fos, c-erbA, v-erbA\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, transient co-transfection; no direct protein-protein interaction demonstrated\",\n      \"pmids\": [\"1349165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"c-erbA alpha (TRα) promoter is a TATA-less, GC-rich promoter containing multiple Sp1 sites. Glucocorticoid (dexamethasone) enhances THRA promoter activity, but thyroid hormone does not, establishing autoregulation of THRA gene expression is not mediated via its own promoter.\",\n      \"method\": \"Transfection of CAT reporter constructs driven by human THRA promoter, hormone treatment of HeLa cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter functional characterization with defined hormone treatments\",\n      \"pmids\": [\"8455948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Stable expression of unliganded c-erbA alpha (TRα1) in mouse neuroblastoma N2a cells induces trkB mRNA expression and protein (gp145trkB) that is phosphorylated on tyrosine in response to BDNF, while concomitantly suppressing trkA and trkC. This TRα1-driven trkB induction is ligand-independent and is also produced by transient expression of TRβ1, indicating a conserved function of unliganded TR in regulating neurotrophin receptor expression.\",\n      \"method\": \"Stable transfection, Northern blot, Western blot, tyrosine phosphorylation assay, BDNF stimulation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — stable expression with defined molecular readout (trkB induction and functional phosphorylation); single lab\",\n      \"pmids\": [\"8134111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"v-erbA oncogenic function in neoplasia best correlates not with suppression of c-erbA/TRα action but with its ability to interfere with retinoic acid receptor (RAR) signaling. v-erbA forms heterodimers with RXR, which dramatically interferes with RXR transcriptional activity. In contrast, v-erbA interferes with thyroid hormone and trans-retinoic acid receptors by competing for DNA response elements, without observable heterodimerization.\",\n      \"method\": \"Co-transfection reporter assays, EMSA for heterodimerization, correlation of transformation with receptor interference\",\n      \"journal\": \"Cell / Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with EMSA, reporter assays, and multiple receptor combinations; replicated across two studies\",\n      \"pmids\": [\"1679679\", \"8105369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Unliganded TRα (c-erbA), but not v-erbA, suppresses RAR-dependent transactivation by titrating out the common dimerization partner RXR. TRα competes with RAR for RXR and dissociates preformed RAR/RXR-RARE complexes in vitro. A single point mutation in the TRα dimerization interface (equivalent to the v-erbA Pro349 position) abolishes this trans-dominant suppression, demonstrating that RXR competition is the mechanism.\",\n      \"method\": \"Co-transfection reporter assays, in vitro EMSA competition, site-directed mutagenesis of dimerization domain\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of complex dissociation plus mutagenesis plus cell-based validation\",\n      \"pmids\": [\"8096810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"c-erbA alpha (TRα) and RARα control commitment of hematopoietic self-renewing progenitor cells to apoptosis or differentiation; both T3 and RA induce apoptosis and strong inhibition of self-renewal in progenitor cells. The v-erbA oncogene renders erythrocytic progenitor cells insensitive to apoptosis and self-renewal inhibition induced by RA or T3, through its transforming activity.\",\n      \"method\": \"Normal erythrocytic progenitor culture, ligand treatment, apoptosis and self-renewal assays, v-erbA retroviral expression\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — primary cell culture with defined ligand treatments and loss-of-function v-erbA; single lab\",\n      \"pmids\": [\"7906409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"TRα (c-erbA alpha/TR alpha-1) expressed in the adrenal medulla progenitor cell line PC12 inhibits NGF-induced neuronal differentiation and represses neuron-specific gene expression in the absence of T3, while permitting normal differentiation in the presence of T3. In the absence of T3, TRα-expressing cells become NGF-responsive for proliferation. TRα also constitutively blocks dexamethasone-induced chromaffin differentiation, revealing a role for TRα in controlling progenitor commitment.\",\n      \"method\": \"Stable retroviral expression of TRα in PC12 cells, NGF and T3 treatment, differentiation and gene expression assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — stable expression system with defined ligand conditions and multiple differentiation readouts; single lab\",\n      \"pmids\": [\"8385673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"v-erbA binds as homodimers to thyroid hormone response elements (TREs), and forms heterodimers with RXR, T3 receptor auxiliary protein (TRAP), and TRα. High concentrations of T3 decrease v-erbA homodimer binding to TREs. Multiple v-erbA complexes (homodimers, heterodimers with RXR/TRAP/TRα) all remain bound to DNA in the presence of T3 and can compete with TR-containing complexes, contributing to dominant negative effects.\",\n      \"method\": \"EMSA with in vitro translated proteins, co-transfection reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct EMSA characterization of multiple complex types; single lab\",\n      \"pmids\": [\"7904604\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"c-ErbA (TRα) but not v-ErbA forms heterodimers with RXR that compete with the erythrocyte-specific nuclear factor NFX for binding to the CAII promoter PAL2 site. This competition displaces the repressor NFX, providing a mechanism by which T3-activated TRα/RXR activates CAII transcription. v-ErbA alone or with RXR fails to compete with NFX, explaining why v-ErbA cannot activate CAII.\",\n      \"method\": \"EMSA competition assays, transfection reporter assays, identification of NFX erythrocyte-specific factor\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — EMSA competition with defined factors; single lab\",\n      \"pmids\": [\"7916146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A nuclear receptor co-repressor (N-CoR) of ~270 kDa physically interacts with thyroid hormone receptor (TRα) and mediates ligand-independent transcriptional repression. N-CoR association with TR is destabilized by T3, providing a molecular mechanism for unliganded TR repression and ligand-induced de-repression.\",\n      \"method\": \"Biochemical purification, co-immunoprecipitation, in vitro protein binding, reporter gene assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical identification and purification of corepressor with functional validation; replicated independently (PMIDs 7566114, 7566127)\",\n      \"pmids\": [\"7566114\", \"7566127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"SMRT (silencing mediator for retinoid and thyroid-hormone receptors) was identified as a corepressor that interacts with thyroid hormone receptor (TRα) in solution and when bound to DNA response elements. This association is destabilized by ligand. In vivo SMRT functions as a potent corepressor of TR-mediated transcription.\",\n      \"method\": \"Protein interaction screen, co-immunoprecipitation, reporter assays, GAL4 fusion repressor assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical interaction and functional demonstration; independent identification alongside N-CoR\",\n      \"pmids\": [\"7566127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Two classes of TR-interacting proteins (TRIPs) were identified by yeast interaction trap: one class interacts with TRβ ligand-binding domain only in the presence of T3 (putative coactivators), another only in its absence (putative corepressors). Neither class interacts with glucocorticoid receptor. Trip4 contains a transcriptional activation domain; Trip9/10 confer indirect T3-dependent activation when co-expressed with TR and RXR in yeast.\",\n      \"method\": \"Yeast interaction trap, in vitro binding, yeast reporter assays\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — yeast two-hybrid with functional validation; identifies ligand-dependent interaction classes\",\n      \"pmids\": [\"7776974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CBP (CREB-binding protein) directly interacts with the ligand-binding domain of multiple nuclear receptors including TRα, and this interaction is required for ligand-dependent transcriptional activation. CBP also interacts with p160 coactivators (SRC-1 variants). Competition between nuclear receptors and AP-1 for limiting amounts of CBP/p300 underlies AP-1 inhibition by TRα.\",\n      \"method\": \"Direct protein interaction assays, co-immunoprecipitation, reporter assays, dominant negative CBP competition\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct interaction demonstrated with multiple orthogonal methods; competition mechanism functionally validated\",\n      \"pmids\": [\"8616895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"TRα purified from HeLa cells grown in the presence of T3 is associated with a group of nuclear proteins termed thyroid hormone receptor-associated proteins (TRAPs), forming a ligand-induced multisubunit coactivator complex. This TR/TRAP complex markedly activates transcription from T3-responsive promoters in cell-free assays. TRα purified without T3 lacks TRAPs and shows only low-level, ligand-dependent activation. RXR is required for TRAP complex function but is not a TRAP component.\",\n      \"method\": \"Biochemical purification from HeLa cells, in vitro transcription reconstitution, T3-dependent complex assembly\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical purification and cell-free reconstituted transcription; ligand-dependence directly demonstrated\",\n      \"pmids\": [\"8710870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"SHP (short heterodimer partner), an orphan nuclear receptor lacking a DNA-binding domain, interacts directly with the thyroid hormone receptor (TRα) via its ligand-binding/dimerization domain in yeast two-hybrid and in vitro binding assays. SHP specifically inhibits TR-dependent transactivation in mammalian cells, functioning as a negative regulator of TR signaling.\",\n      \"method\": \"Yeast two-hybrid, in vitro binding assay, co-transfection reporter assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — two independent methods (yeast two-hybrid + in vitro binding) with functional validation; single lab\",\n      \"pmids\": [\"8650544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"ACTR, a nuclear receptor coactivator, directly binds TRα (and other nuclear receptors) in a hormone-dependent manner and recruits CBP and P/CAF to form a multisubunit coactivator complex. ACTR itself possesses intrinsic histone acetyltransferase (HAT) activity, establishing that TRα activation involves coordinated HAT activity from at least three enzymes (ACTR, CBP, P/CAF).\",\n      \"method\": \"Direct protein binding assays, co-immunoprecipitation, in vitro HAT assay with purified ACTR\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified protein HAT assay plus multi-component complex reconstitution\",\n      \"pmids\": [\"9267036\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"v-ErbA can substitute for the ligand-activated glucocorticoid receptor (GR) and estrogen receptor (ER) to induce proliferation and arrest differentiation of erythroid progenitors, and requires cooperation with c-Kit (receptor tyrosine kinase) for both activities. v-ErbA's biological activities depend on distinct mutations in the DNA-binding domain. v-ErbA acts as a weak, partial repressor of c-ErbA/TRα function (not fully dominant negative) in normal erythroblasts; full dominant-negative activity requires restoration of RXR heterodimerization capacity.\",\n      \"method\": \"Retroviral expression in erythroid progenitors, GR/ER antagonist treatment, c-Kit dependency analysis, RXR heterodimerization mutant rescue\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic dissection of v-erbA mechanisms in primary progenitor cells; single lab\",\n      \"pmids\": [\"9264411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TRAP220, a component of the TRAP coactivator complex, directly interacts with TRα (and other nuclear receptors) in a ligand-dependent manner through its LXXLL motifs engaging the C-terminus of TRα. A fragment containing LXXLL motifs acts as a dominant negative inhibitor of nuclear receptor-mediated transcription. TRAP220 plays a central role in anchoring other TRAPs to TRα.\",\n      \"method\": \"Co-immunoprecipitation, direct binding assays, transfection reporter assays, cell-free transcription assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct binding with defined motifs, cell-free transcription reconstitution, dominant negative validation\",\n      \"pmids\": [\"9653119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"NSD1, a novel nuclear protein with SET domain and PHD fingers, contains two distinct TR interaction domains (NID-L and NID+L) with opposing properties: NID-L interacts with unliganded TRα LBD (requiring helix 1 integrity, like corepressors), while NID+L interacts with liganded TRα LBD (requiring helix 12, like coactivators). NSD1 contains both repression and activation domains, functioning as a bifunctional transcriptional intermediary factor.\",\n      \"method\": \"Yeast two-hybrid, in vitro pull-down with defined LBD mutants, transient transfection reporter assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — systematic mutagenesis of both receptor and cofactor with multiple interaction assays demonstrating mechanistic basis\",\n      \"pmids\": [\"9628876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"v-ErbA constitutively binds to the carbonic anhydrase II (CAII) gene intronic erythroid enhancer element (HS2-VRE) in vivo in transformed undifferentiated erythroblasts, as shown by in vivo footprinting. This binding co-occurs with GATA-1. Treatment with histone deacetylase inhibitor trichostatin A derepresses the chromatin-embedded endogenous CAII gene but not a transfected construct, demonstrating that HDAC activity is required for v-ErbA repression at the endogenous chromatin-embedded locus.\",\n      \"method\": \"In vivo footprinting, retroviral expression assays, trichostatin A treatment, transfection assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vivo footprinting directly demonstrates receptor-chromatin binding; pharmacological dissection of HDAC requirement\",\n      \"pmids\": [\"9857194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The TRAP complex (thyroid hormone receptor-associated proteins) is virtually identical to the SMCC (SRB- and MED-containing cofactor complex) that mediates transcriptional activation by p53. TRAP80 directly interacts with p53 and VP16 activation domains. The TRAP220/SMCC220 subunit binds liganded TRα. This establishes that TRα and other activators share a common coactivator complex targeting RNA Pol II.\",\n      \"method\": \"Mass spectrometry of purified complexes, direct protein binding assays, reporter assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mass spectrometry identification combined with direct protein interaction and functional data\",\n      \"pmids\": [\"10198638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Ligand-dependent activation by TRα requires the DRIP complex (distinct from TRAP only by nomenclature in context of VDR). The DRIP complex mediates ligand-dependent enhancement of transcription by TRα in cell-free transcription assays on chromatin templates, establishing DRIPs as positive coactivators for TRα.\",\n      \"method\": \"Cell-free transcription assay on chromatin templates, biochemical purification of DRIP complex\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cell-free reconstitution on chromatin templates with purified complex\",\n      \"pmids\": [\"10235266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"v-ErbA and TRα both recruit N-CoR and concomitantly HDAC3 (without association with Sin3, HDAC1/RPD3, Mi-2, or HDAC5) on thyroid hormone-responsive templates in Xenopus oocytes. v-ErbA repression is more HDAC-inhibitor sensitive than TRα repression and requires mature chromatin (v-ErbA cannot repress on partly chromatinized templates). v-ErbA is less competent than TRα for binding TFIIB in vitro and in vivo, explaining reduced repression on non-chromatinized templates.\",\n      \"method\": \"Xenopus oocyte injection, chromatin immunoprecipitation, HDAC inhibitor treatment, in vitro TFIIB binding assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vivo chromatin assay in oocytes, ChIP, in vitro binding, pharmacological dissection; multiple orthogonal methods\",\n      \"pmids\": [\"10921888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"A targeted mutation (Thra(tm2)) in the mouse Thra gene that deletes TRα2 and causes overexpression of TRα1 suppresses deafness and thyroid hyperactivity phenotypes caused by Thrb-null mutation. This demonstrates that increased TRα1 expression can functionally substitute for TRβ in auditory and thyroid functions, revealing significant functional overlap between TR isotypes.\",\n      \"method\": \"Mouse genetics (targeted deletion), auditory threshold testing, thyroid function assays, genetic epistasis in double-mutant mice\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic epistasis in mouse model with multiple quantitative phenotypic readouts\",\n      \"pmids\": [\"11726557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"v-ErbA dimerizes with TRα and RXR and sequesters a significant fraction of both nuclear receptors in the cytoplasm, partially reversing their normal nuclear localization. Ligand and histone deacetylase inhibitor (trichostatin A) partially restore TRα nuclear localization. This defines cytoplasmic sequestration as an additional dominant-negative mechanism for v-ErbA distinct from DNA competition.\",\n      \"method\": \"Subcellular fractionation, co-immunoprecipitation, immunofluorescence microscopy, histone deacetylase inhibitor treatment\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization with fractionation and imaging, co-IP for dimerization; single lab\",\n      \"pmids\": [\"15650025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"T3 activates PI3-kinase via Src kinase signaling through an αvβ3 integrin receptor, and PI3-kinase activity mediates shuttling of nuclear TRα from cytoplasm to nucleus. LY-294002 (PI3-kinase inhibitor) blocks T3-induced TRα nuclear translocation and HIF-1α mRNA accumulation. This establishes a non-genomic T3 signaling pathway regulating TRα subcellular localization.\",\n      \"method\": \"PI3-kinase inhibitor treatment, siRNA knockdown of PI3-kinase, subcellular localization assays, integrin antagonist experiments\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and siRNA validation of PI3-kinase requirement for TRα trafficking; single lab\",\n      \"pmids\": [\"19158403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Truncating and missense mutations in the THRA gene cause resistance to thyroid hormone alpha (RTHα) with a consistent phenotype including growth retardation, macrocephaly, skeletal dysplasia, mental retardation, low fT4/high fT3 ratio, and anemia. A genotype-phenotype correlation was established: truncating mutations cause more severe phenotypes than missense mutations. Whole exome sequencing identified THRA as the causative gene.\",\n      \"method\": \"Whole exome sequencing, Sanger sequencing confirmation, clinical/biochemical characterization of 6 patients from 5 families\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — genotype-phenotype correlation in human patients; molecular mechanism inferred from mutation type\",\n      \"pmids\": [\"25670821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A de novo missense mutation in THRA (N359Y) affecting TRα1 causes RTHα with severe bone malformation, dwarfism, and macrocytic anemia. The mutant TRα1(N359Y) has decreased T3 binding affinity and dominant-negative effect on wild-type TRα1 in transcriptional assays, with low resting energy expenditure normalized by T3 treatment.\",\n      \"method\": \"Whole exome sequencing, in vitro transcription assay, T3 binding assay, clinical T3 treatment trial\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional characterization of mutant receptor in vitro with clinical correlation; single case\",\n      \"pmids\": [\"26037512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CRISPR/Cas9 editing of the mouse Thra gene producing frameshift or missense mutations recapitulates human RTHα with variable phenotype severity. Phenotype severity correlates with the ability of the mutant TRα1 to interact with transcriptional corepressors in the presence of thyroid hormone (i.e., corepressor release by T3 is impaired in proportion to severity).\",\n      \"method\": \"CRISPR/Cas9 genome editing, mouse phenotypic analysis, corepressor interaction assay in presence/absence of T3\",\n      \"journal\": \"Thyroid\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic models with multiple alleles, phenotypic characterization, and defined molecular mechanism (corepressor release)\",\n      \"pmids\": [\"29205102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"THRA missense mutations M259T and T273A in RTHα patients reduce TRα1 affinity for T3, such that corepressors fail to dissociate from the mutant receptor even in the presence of T3. In silico modeling combined with T3 binding assays and corepressor interaction assays demonstrates that the severity of RTHα correlates with reduction in T3 binding affinity and the consequent inability to release corepressors.\",\n      \"method\": \"Biochemical T3 binding assays, corepressor interaction assays, in silico structural modeling, cellular transcriptional assays\",\n      \"journal\": \"Thyroid\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical methods with structural modeling; small patient series\",\n      \"pmids\": [\"32204686\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"THRA encodes thyroid hormone receptor alpha (TRα), a ligand-dependent nuclear transcription factor that, when unliganded, recruits corepressors (N-CoR, SMRT) and HDAC3 to silence target genes, and upon T3 binding releases corepressors and assembles a multisubunit coactivator complex (TRAP/DRIP containing CBP, ACTR, TRAP220/MED1, and related HATs) via its conserved C-terminal AF-2 helix—functioning primarily as RXRα heterodimers on direct-repeat response elements; phosphorylation by CK2 (Ser12) and PKA/PKC (Ser28/29) modulates its activity; alternative splicing generates a non-T3-binding TRα2 isoform that acts as a dominant inhibitor of TRα1; and loss-of-function THRA mutations that impair T3 binding or corepressor release cause resistance to thyroid hormone alpha (RTHα) with growth retardation, skeletal dysplasia, and macrocephaly.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"THRA encodes thyroid hormone receptor alpha (TRα1), a ligand-dependent nuclear transcription factor that functions as a molecular switch: in the absence of T3, TRα1 recruits the N-CoR/HDAC3 corepressor complex to repress target genes, while T3 binding triggers corepressor release and transcriptional activation through a conserved 9-amino-acid C-terminal activation domain [PMID:10921888, PMID:8098843, PMID:2158623]. Alternative splicing generates TRα2, which binds DNA but not T3 and antagonizes TRα1 activity; the ratio of these isoforms is regulated by Rev-ErbAα antisense RNA transcribed from the opposite strand of the THRA locus [PMID:2537467, PMID:1657988]. TRα1 is phosphorylated by casein kinase II at Ser12 and by PKA/PKC at Ser28/29, modifications required for full transcriptional and oncogenic activity [PMID:2903825, PMID:2552374, PMID:1979040]. Loss-of-function mutations in THRA cause resistance to thyroid hormone alpha (RTHα), with disease severity correlating with the degree to which mutant receptors retain corepressor interaction in the presence of T3 [PMID:26037512, PMID:29205102, PMID:32204686].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Establishing that TRα1 is a bona fide ligand-dependent transcription factor answered the question of whether the c-erbA proto-oncogene product has direct transcriptional activity, by showing it confers T3-responsive gene regulation when introduced into receptor-deficient cells.\",\n      \"evidence\": \"Retroviral expression of cTRα in T3 receptor-deficient rat hepatoma cells restored T3-dependent regulation of multiple endogenous genes\",\n      \"pmids\": [\"2158623\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of DNA target selection not defined\", \"Coactivator/corepressor partners not yet identified\", \"Post-translational regulation not addressed\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Identification of phosphorylation sites on TRα1 revealed that the receptor is post-translationally modified at two N-terminal serine clusters by PKA/PKC (Ser28/29) and casein kinase II (Ser12), establishing a signaling input to receptor function.\",\n      \"evidence\": \"Metabolic labeling, tryptic phosphopeptide mapping, and in vitro kinase assays with purified kinases and site-directed mutants\",\n      \"pmids\": [\"2903825\", \"2552374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of phosphorylation on transcriptional activity not yet tested\", \"In vivo relevance of individual phosphorylation events unknown\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Discovery that v-erbA acts as a constitutive dominant-negative repressor of TRα1-mediated transcription resolved how a thyroid hormone receptor derivative becomes oncogenic—by losing hormone-dependent activation while retaining DNA binding and transcriptional repression.\",\n      \"evidence\": \"Transient transfection reporter assays and co-expression experiments in multiple cell lines\",\n      \"pmids\": [\"2733791\", \"2830979\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Corepressor identity unknown at this stage\", \"Whether repression requires chromatin context not determined\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Identification of TRα2 as an alternatively spliced product that binds DNA but not T3 and inhibits TRα1 activity established an endogenous mechanism of hormonal antagonism encoded within the same gene.\",\n      \"evidence\": \"cDNA cloning, in vitro T3 binding assays, and transient transfection reporter assays; replicated by multiple laboratories\",\n      \"pmids\": [\"2537467\", \"2903438\", \"2554288\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo ratio of α1 to α2 and its physiological regulation not established\", \"Whether TRα2 has any independent function beyond antagonism unknown\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Structure-function mapping of the hormone-binding domain to the C-terminal half and identification of a region between the DBD and LBD important for transcriptional regulation (but not ligand binding) defined the modular architecture of TRα1.\",\n      \"evidence\": \"Chimeric c-erbA/v-erbA proteins analyzed by ligand binding assays\",\n      \"pmids\": [\"3359993\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise boundaries of activation domains not mapped\", \"Role of the hinge region in corepressor interaction not addressed\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Demonstrating that phosphorylation at Ser16/17 of v-erbA is required for biological activity (erythroid transformation) without affecting DNA binding linked post-translational modification directly to oncogenic function, answering whether phosphorylation is functionally consequential.\",\n      \"evidence\": \"Alanine substitution mutagenesis, erythroid differentiation assays, and pharmacological kinase inhibition with H7\",\n      \"pmids\": [\"1979040\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the kinase responsible in vivo not confirmed\", \"Whether phosphorylation alters corepressor/coactivator interactions unknown\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Mapping the loss of hormone-dependent activation to a conserved C-terminal amphipathic helix deleted in v-erbA identified the activation function-2 (AF-2) domain as the critical switch between repressor and activator states.\",\n      \"evidence\": \"Chimeric v-/c-erbA protein expression in erythroid cells with transcription and differentiation readouts\",\n      \"pmids\": [\"1972036\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors recruited by this helix not identified\", \"Structural basis of the switch unknown\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Discovery that Rev-ErbAα antisense RNA inhibits TRα2 splicing in vitro revealed a cis-regulatory mechanism at the THRA locus controlling the balance between the functional receptor and its antagonist.\",\n      \"evidence\": \"In vitro splicing assay with antisense RNA addition and specificity controls\",\n      \"pmids\": [\"1657988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of antisense-mediated splice regulation not demonstrated\", \"Quantitative impact on TRα1/TRα2 ratio in tissues unknown\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Systematic mutagenesis of a conserved 9-amino-acid C-terminal motif established that this single element is essential for T3-dependent activation, AP-1 cross-repression, and erythroid differentiation, unifying three activities in one structural determinant.\",\n      \"evidence\": \"Single/double/triple amino acid substitutions in c-erbA and homologous RAR deletions with multiple functional assays\",\n      \"pmids\": [\"8098843\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding partners of this motif not identified\", \"Whether this motif recruits coactivators versus releases corepressors not resolved\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Demonstration that unliganded TRα1 competes with RAR for the shared dimerization partner RXR, and that a v-erbA dimerization interface mutation abolishes this competition, established RXR sequestration as a mechanism of cross-talk between thyroid hormone and retinoid signaling.\",\n      \"evidence\": \"Co-transfection assays, in vitro competition EMSA, and site-directed mutagenesis\",\n      \"pmids\": [\"8096810\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance in tissues co-expressing TRα1 and RAR not tested\", \"Stoichiometry of RXR competition in vivo unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"In vivo footprinting showing constitutive v-erbA occupancy at an intronic CAII element, with HDAC inhibitor-mediated derepression, established that v-erbA/TRα repression operates through histone deacetylation at endogenous chromatin-embedded targets.\",\n      \"evidence\": \"In vivo footprinting in transformed erythroblasts, VRE mutagenesis, and trichostatin A treatment\",\n      \"pmids\": [\"9857194\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific HDAC complex recruited to this element not identified\", \"Genome-wide extent of constitutive occupancy unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identification of N-CoR/HDAC3 (but not Sin3/HDAC1) as the specific corepressor complex recruited by both v-erbA and TRα1 answered which deacetylase mediates transcriptional repression and explained the HDAC inhibitor sensitivity observed at target genes.\",\n      \"evidence\": \"Co-immunoprecipitation, Xenopus oocyte chromatin assembly, HDAC inhibitor experiments, and in vitro TFIIB binding assay\",\n      \"pmids\": [\"10921888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether additional corepressor complexes participate at specific loci unknown\", \"Structural basis of N-CoR/HDAC3 selectivity not determined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Genetic epistasis showing that increased TRα1 expression (from TRα2 deletion) compensates for absent TRβ in hearing and thyroid regulation demonstrated functional redundancy between TR isoforms and that TRα2 is dispensable for these processes.\",\n      \"evidence\": \"Double-mutant mice (Thra tm2 × Thrb null) with auditory threshold testing and thyroid function assays\",\n      \"pmids\": [\"11726557\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether compensation occurs in all TRβ-dependent tissues not tested\", \"Mechanism of increased TRα1 expression from the targeted allele not fully characterized\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identification of THRA loss-of-function mutations as the cause of resistance to thyroid hormone alpha (RTHα), with biochemical demonstration that mutant TRα1 has reduced T3 binding and dominant-negative activity, established a direct genotype-phenotype relationship.\",\n      \"evidence\": \"Whole exome sequencing, T3 binding assays, transcriptional reporter assays, and dominant-negative testing\",\n      \"pmids\": [\"26037512\", \"25670821\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full spectrum of THRA mutations causing RTHα not catalogued\", \"Tissue-specific effects of mutations not mechanistically dissected\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"CRISPR-generated mouse Thra mutations recapitulating RTHα with severity proportional to mutant receptor-corepressor retention in the presence of T3 established the corepressor release defect as the primary pathogenic mechanism.\",\n      \"evidence\": \"CRISPR/Cas9 genome editing with phenotypic characterization and corepressor interaction assays\",\n      \"pmids\": [\"29205102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether corepressor-targeted therapies can rescue the phenotype not tested\", \"Contribution of dominant-negative versus haploinsufficiency mechanisms not fully separated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Novel RTHα mutations (M259T, T273A) confirmed that failure of T3-dependent corepressor dissociation, not merely reduced T3 binding, is the proximal cause of disease severity, refining the mechanistic model.\",\n      \"evidence\": \"Biochemical T3 binding assays, corepressor interaction assays, structural modeling, and transcriptional reporter assays\",\n      \"pmids\": [\"32204686\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of corepressor retention at atomic resolution not resolved\", \"Whether pharmacological chaperones or selective modulators can overcome corepressor retention unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the genome-wide map of TRα1-occupied enhancers and their chromatin states in vivo, the structural basis of the corepressor-to-coactivator switch at atomic resolution, and whether tissue-specific cofactor availability explains the organ-selective phenotypes of RTHα mutations.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No genome-wide ChIP-seq map of endogenous TRα1 occupancy published in timeline\", \"Atomic-resolution structure of TRα1 in complex with N-CoR/HDAC3 not available\", \"Tissue-specific cofactor expression profiles not linked to RTHα phenotype severity\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 3, 8, 11, 15, 30]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 6, 8, 10, 11, 12, 17, 27]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 9, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5, 17, 21, 27]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [17, 20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 6, 10, 11, 17, 27]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 12, 13, 28]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 12, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [23, 24, 25, 26]}\n    ],\n    \"complexes\": [\n      \"N-CoR/HDAC3 corepressor complex\"\n    ],\n    \"partners\": [\n      \"RXRA\",\n      \"NCOR1\",\n      \"HDAC3\",\n      \"CSNK2A1\",\n      \"TFIIB\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"THRA encodes thyroid hormone receptor alpha (TRα), a ligand-dependent nuclear transcription factor that functions primarily as an RXRα heterodimer on direct-repeat thyroid hormone response elements to control programs of erythroid, neuronal, and skeletal differentiation [PMID:1310350, PMID:8385673, PMID:1972036]. In the unliganded state, TRα recruits the corepressors N-CoR and SMRT together with HDAC3 to silence target genes; T3 binding triggers corepressor release and assembly of a multisubunit coactivator complex (TRAP/DRIP–Mediator) anchored by TRAP220/MED1 via LXXLL motifs, with additional recruitment of CBP, ACTR, and P/CAF providing coordinated histone acetyltransferase activity [PMID:7566114, PMID:8710870, PMID:9653119, PMID:9267036]. Alternative splicing generates TRα2, a non-T3-binding isoform that acts as a dominant inhibitor of TRα1, and phosphorylation by CK2 (Ser12) and PKA/PKC (Ser28/29) further modulates receptor activity [PMID:2537467, PMID:2552374, PMID:2903825]. Loss-of-function THRA mutations that reduce T3 binding affinity and impair corepressor release cause resistance to thyroid hormone alpha (RTHα), characterized by growth retardation, skeletal dysplasia, macrocephaly, and anemia [PMID:25670821, PMID:29205102].\",\n  \"teleology\": [\n    {\n      \"year\": 1986,\n      \"claim\": \"Identification of c-erbA as a high-affinity T3/T4 receptor established that a known proto-oncogene is a nuclear hormone receptor, resolving the molecular identity of the thyroid hormone receptor.\",\n      \"evidence\": \"Hormone binding assays and nuclear localization studies comparing c-erbA and v-erbA proteins\",\n      \"pmids\": [\"2879242\", \"2879243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No information on DNA target specificity\", \"Structure of the receptor unknown\", \"Mechanism of transcriptional regulation not addressed\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Discovery of alternative splicing generating TRα2 (non-T3-binding) and identification of PKA/CK2 phosphorylation sites revealed two major regulatory axes—isoform diversity and post-translational modification—that modulate TRα function independently of ligand.\",\n      \"evidence\": \"cDNA cloning and in vitro T3 binding showing TRα2 lacks hormone binding; tryptic phosphopeptide mapping and in vitro kinase assays with purified PKA and CK2 identifying Ser12 and Ser28/29\",\n      \"pmids\": [\"2537467\", \"2903825\", \"2552374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of phosphorylation on transcriptional activity not determined\", \"Physiological role of TRα2 in vivo unknown\", \"No structural basis for why TRα2 cannot bind T3\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Mapping the C-terminal activation domain and demonstrating that unliganded TRα is a transcriptional repressor (while T3 converts it to an activator) established the dual-function switch model and defined the functional importance of the AF-2 helix region.\",\n      \"evidence\": \"Chimeric v-erbA/c-erbA protein analysis, co-transfection reporter assays, and erythroid differentiation assays\",\n      \"pmids\": [\"2733791\", \"8098843\", \"1972036\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No cofactors identified that mediate repression or activation\", \"No structural model of the AF-2 region\", \"Mechanism of AP-1 interference unclear\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Demonstration that RXRα is the obligate heterodimerization partner for stable TRα DNA binding and transcriptional activity resolved how TRα engages response elements and explained why unliganded TRα can sequester RXR from RAR, suppressing retinoic acid signaling.\",\n      \"evidence\": \"Biochemical co-purification, EMSA, co-transfection reporter assays, and mutagenesis of the dimerization interface\",\n      \"pmids\": [\"1310350\", \"1314167\", \"8096810\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of TRα/RXR heterodimer not available\", \"In vivo relevance of RXR competition with RAR not established in genetic models\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of N-CoR and SMRT as corepressors that bind unliganded TRα and are released upon T3 binding provided the molecular basis for the repression-to-activation switch.\",\n      \"evidence\": \"Biochemical purification, co-immunoprecipitation, in vitro binding, and reporter gene assays\",\n      \"pmids\": [\"7566114\", \"7566127\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin context of corepressor recruitment not yet examined\", \"Identity of the histone-modifying activity in the corepressor complex unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Purification of the TRAP coactivator complex from T3-treated cells and demonstration of CBP recruitment established that ligand-activated TRα assembles a multisubunit coactivator platform linking to general transcription machinery.\",\n      \"evidence\": \"Biochemical purification from HeLa cells, cell-free transcription assays on T3-responsive promoters, direct interaction assays for CBP\",\n      \"pmids\": [\"8710870\", \"8616895\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Subunit composition of TRAP complex not fully resolved\", \"Sequential versus simultaneous coactivator recruitment not distinguished\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of TRAP220/MED1 as the LXXLL-motif-containing anchor subunit for TR, and of ACTR as a HAT-containing coactivator, completed the picture of a coordinated multi-HAT coactivator assembly (ACTR + CBP + P/CAF) recruited to TRα via TRAP220.\",\n      \"evidence\": \"Direct binding assays with LXXLL motif mutants, dominant negative TRAP220 fragments, purified ACTR HAT assays, cell-free transcription\",\n      \"pmids\": [\"9653119\", \"9267036\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Order of coactivator recruitment to endogenous chromatin not defined\", \"No genome-wide map of TRα-occupied enhancers\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"ChIP-based demonstration that TRα and v-erbA recruit N-CoR with HDAC3 (excluding Sin3, HDAC1, Mi-2) on chromatinized templates in vivo defined the specific HDAC complex used for TRα-mediated repression.\",\n      \"evidence\": \"Xenopus oocyte ChIP, HDAC inhibitor treatment, in vitro TFIIB binding assays\",\n      \"pmids\": [\"10921888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the same N-CoR/HDAC3 complex operates at mammalian endogenous loci not confirmed\", \"No structural basis for selective HDAC3 recruitment over other HDACs\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Discovery that loss-of-function THRA mutations cause resistance to thyroid hormone alpha (RTHα) in humans linked the molecular mechanism of impaired T3 binding and corepressor release to a defined clinical syndrome of growth retardation, skeletal dysplasia, and macrocephaly.\",\n      \"evidence\": \"Whole exome sequencing in patient cohorts, in vitro T3 binding and transcriptional assays of mutant TRα1\",\n      \"pmids\": [\"25670821\", \"26037512\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Small patient numbers limit genotype-phenotype generalization\", \"Tissue-specific consequences of mutations not dissected\", \"No rescue experiments in patient-derived cells\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"CRISPR-generated mouse models established that RTHα phenotype severity correlates directly with the degree to which mutant TRα1 retains corepressor binding in the presence of T3, providing a unifying mechanistic explanation for genotype-phenotype variability.\",\n      \"evidence\": \"CRISPR/Cas9 editing of mouse Thra with multiple alleles, phenotypic analysis, corepressor interaction assays ± T3\",\n      \"pmids\": [\"29205102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether pharmacological corepressor displacement can rescue phenotypes not tested\", \"Contribution of non-genomic TRα signaling to RTHα phenotype unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The genome-wide chromatin landscape of TRα1 occupancy, the structural basis of isoform-specific coactivator/corepressor selectivity, and the physiological role of TRα2 in vivo remain incompletely resolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No genome-wide ChIP-seq map of endogenous TRα1 binding in key tissues\", \"TRα2 knockout phenotype not fully characterized\", \"Structural basis for HDAC3-selective recruitment unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 5, 6, 8, 20, 21]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 4, 19, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 41, 46, 47]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [6, 8, 20, 21, 31, 35, 37]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 9, 47]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [11, 27, 28, 45]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [48, 49, 50]}\n    ],\n    \"complexes\": [\n      \"TRAP/Mediator complex\",\n      \"TRα/RXRα heterodimer\",\n      \"N-CoR/SMRT/HDAC3 corepressor complex\"\n    ],\n    \"partners\": [\n      \"RXRA\",\n      \"NCOR1\",\n      \"NCOR2\",\n      \"HDAC3\",\n      \"MED1\",\n      \"NCOA3\",\n      \"CREBBP\",\n      \"NR0B2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}